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CHAPTER 1
                  Cancer: the never ending nightmare
3
Cancer  continues to be a worldwide killer,  despite the enormous amount  of research and rapid 
developments seen during the past decade. According to recent statistics, cancer accounts for about 
23% of the total  deaths in the USA and is the second most common cause of death after heart 
disease. Death rates for heart disease, however, have been steeply decreasing in both older and 
younger populations in the USA from 1975 through 2002. In contrast, no appreciable differences in 
death rates for cancer have been observed in the United States.
Cancer  is  caused by both internal  factors  (such as inherited  mutations,  hormones,  and immune 
conditions)  and  environmental/acquired  factors  (such  as  tobacco,  diet,  radiation,  and  infectious 
organisms; Fig. 1.1). The link between diet and cancer is revealed by the large variation in rates of 
specific cancers in various countries and by the observed changes in the incidence of cancer in 
migrating. For example, Asians have been shown to have a 25 times lower incidence of prostate 
cancer and a ten times lower incidence of breast cancer than do residents of Western countries, and 
the rates for these cancers increase substantially after Asians migrate to the West.1
Figure 1.1 Suddivision between genetic and environmental causes.1
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Main cause of cancer insurgence and development.
Diet and Exercise.
The importance of lifestyle  factors  in the development  of cancer  was also shown in studies of 
monozygotic twins. Only 5–10% of all cancers are due to an inherited gene defect. Although all 
cancers  are  a  result  of  multiple  mutations,  these  mutations  are  due  to  interaction  with  the 
environment. These observations indicate that most cancers are not of hereditary origin and that 
lifestyle  factors,  such  as  dietary  habits,  smoking,  alcohol  consumption,  and  infections,  have  a 
profound influence on their development. Although the hereditary factors cannot be modified, the 
lifestyle  and environmental factors are potentially modifiable. The lesser hereditary influence of 
cancer and the modifiable nature of the environmental factors point to the preventability of cancer. 
The important lifestyle factors that affect the incidence and mortality of cancer include tobacco, 
alcohol, diet, obesity, infectious agents, environmental pollutants, and
radiation. 1 
In the United States, overweight and obesity contribute to 14% to 20% of all cancer-related
mortality. Overweight and obesity are clearly associated with increased risk for developing
many cancers,  including  cancers  of  the  breast  in  postmenopausal  women  ,colon,  endometrium, 
adenocarcinoma  of  the  esophagus,  and  kidney.  Evidence  is  highly suggestive  that  obesity  also 
increases risk for cancers of the pancreas, gallbladder, thyroid, ovary, and cervix, and for multiple 
myeloma, Hodgkin lymphoma, and aggressive prostate cancer.
These findings are supported by both epidemiologic studies in humans and other research.
Overweight and obesity are thought to affect risk of these cancers through a variety of mechanisms, 
some of which are specific to particular cancer types. These mechanisms include effects on fat and 
sugar metabolism; immune function; levels of several hormones, including insulin and estradiol; 
factors that regulate cell proliferation and growth, such as insulin-like growth factor-1; and proteins 
that make hormones more or less available to tissues, such as sex hormone-binding globulin.
Overweight and obesity may increase risk of adenocarcinoma of the esophagus by increasing risk of 
gastroesophageal reflux disease and Barrett’s esophagus.
Most  research  on  energy  imbalance  and  cancer  focuses  on  increased  risks  associated  with 
overweight  and  obesity.  Recently,  studies  exploring  intentional  weight  loss  suggest  that  losing 
weight may reduce the risk of breast cancer.
Surgery to treat morbid obesity and short-term intentional weight loss have been shown to improve 
insulin sensitivity and biochemical measures of hormone metabolism, which have been
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postulated  to  contribute  to  the  relationship  between  obesity  and  certain  cancers.  The  surgical 
removal of intra-abdominal fat has also been shown to reduce the metabolic syndrome.
Even  though  our  knowledge  about  the  relationship  between  weight  loss  and  cancer  risk  is 
incomplete, individuals who are overweight or obese should be encouraged and supported in their 
efforts to reduce weight. 2  
Chemicals.
A very large amount  of organic and inorganic compounds are deputed or suspected to provoke 
cancer.
It should be an infinite list.
Among  the  most  prominent  we  can  cite  chemicals  released  from  tobacco  burning  (such  as 
nitrosamine and polycyclic aromatic hydrocarbons), asbestos, benzene, alcoholic beverage. 3
Infection.
Worldwide  approximately 18% of  cancers  are  related  to  infectious  diseases.[1]  This  proportion 
varies in different  regions of the world from a high of 25% in Africa to less than 10% in the 
developed world. 1
Viruses are the usual infectious agents that cause cancer but bacteria and parasites may also have an 
effect.
A  virus  that  can  cause  cancer  (called  oncovirus)  include  human  papillomavirus  (cervical 
carcinoma), Epstein-Barr virus (B-cell lymphoproliferative disease and nasopharyngeal carcinoma), 
Kaposi's sarcoma herpesvirus (Kaposi's Sarcoma and primary effusion lymphomas), hepatitis B and 
hepatitis  C  viruses  (hepatocellular  carcinoma),  and  Human  T-cell  leukemia  virus-1  (T-cell 
leukemias). Bacterial infection may also increase the risk of cancer, as seen in Helicobacter pylori-
induced  gastric  carcinoma.[23]  Parasitic  infections  strongly  associated  with  cancer  include 
Schistosoma  haematobium  (squamous  cell  carcinoma  of  the  bladder)  and  the  liver  flukes, 
Opisthorchis viverrini and Clonorchis sinensis (cholangiocarcinoma). 4
Radiation.
Principal  Cellular and Tissue Effects  of Radiation can be resumed in:  cell  killing,  mutagenesis, 
chromosomal aberrations and neoplastic transformations.
6
Radiation can kill cells by two distinct mechanisms. The first is apoptosis, also called programmed 
cell death or interphase death. Cells undergoing apoptosis as an immediate consequence of radiation 
damage usually die  in interphase within a few hours of irradiation,  irrespective  of and without 
intervening  mitosis. The  second  mechanism  for  cell  killing  is  radiation-induced  reproductive 
failure.  Radiation in sufficient  doses can inhibit  mitosis;  that  is,  the cell’s  ability to divide and 
proliferate indefinitely. The inhibition of cellular proliferation is the mechanism by which radiation 
kills most cells.
The major potential consequence of radiation-induced mutations in human populations is heritable 
genetic effects resulting from mutations induced in germinal cells. 5
Hormones.
Neoplasia  of  hormone-responsive  tissues  currently  accounts  for  more  than  35%  of  all  newly 
diagnosed male and more than 40% of all newly diagnosed female cancers in the United States. 
Given  that  endogenous  hormones  apparently  affect  the  risk  of  these  cancers  and  their  overall 
frequency, concern exists about the effects on cancer risk if the same or closely related hormones 
are administered for therapeutic purposes.
Oral contraccettive
The relationship of oral contraccettive (OC) use to breast cancer risk has been the topic of many 
review articles. A recent combined analysis of 54 studies that included over 150,000 women has 
provided many important answers about the risk of breast cancer among users of combination OC 
(COC), i.e.,  OCs which provide an estrogen and progestin in combination in a single pill.  This 
analysis indicates that a modest increased risk of breast cancer is observed among current (relative 
risk, RR = 1.24) and recent (RR = 1.16) COC users. Age at first COC use modifies the association 
with recent use. For recent users, the risks are highest for those who began COC use before the age 
of 20 years. However, total duration of COC use was not associated with increased risk of breast 
cancer, once recency of use was taken into account. Although the scope of this combined analysis 
was broad, it still provides little information on COC effects 10 or more years after cessation of use. 
Moreover,  most  women who stopped use 10 or more years  ago had used COCs for only short 
periods  of  time.  Women  who  began  use  as  teenagers  are  now becoming  perimenopausal  and 
postmenopausal. Current studies now underway will be able to examine more complex patterns of 
COC use, as related to breast cancer risk.
7
Hormone replacement terapy
Hormone  replacement  therapy  in  the  form  of  unopposed  estrogen  therapy  gained  widespread 
popularity in the United States during the 1960s and 1970s. Concomitant with this increasing usage, 
incidence rates of endometrial cancer in postmenopausal women also increased rapidly, especially 
on  the  West  Coast,  where  use  of  ERT  was  particularly  common. By  1975,  the  results  of 
epidemiologic case-control studies, demonstrating a strong overall association between ERT and 
risk of endometrial cancer were being published. Literally dozens of studies have now documented 
a high relative increase in the risk of endometrial cancer following ERT. Risk is strongly related 
both to dose and duration of use, but high relative increments in risk follow even moderate doses 
taken  for  moderately  long  periods  of  time.  Women  who use  ERT for  5  years  or  longer  have 
approximately a 3.5-fold increase in risk compared with that of women who have never used such 
therapy. 6
A lot of therapies exist,  but even if cancer treatments have lead to prolonged life-span, no one 
definitive treatment is yet in use. 
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CHAPTER 2
         Matrix Metalloproteinases: An introduction.
10
Matrix  metalloproteinases  (MMPs)  are  an  important  family  of  zinc-  and  calcium-dependent 
peptidases  involved  in  the  regulation  of  the  cellular  behavior  by  proteolytic  processing  of  the 
pericellular environment.  1 The founding member of the matrix metalloproteinase (MMP) family, 
collagenase,  was  identified  in  1962 by Gross and Lapiere,  who found that  tadpole  tails  during 
metamorphosis  contained  an enzyme  that  could degrade fibrillar  collagen IV.  Subsequently,  an 
interstitial collagenase, collagenase-1 or MMP1, was found in diseased skin and synovium. In vitro, 
MMP1  initiates  degradation  of  native  fibrillar  collagens,  crucial  components  of  vertebrate 
extracellular matrix, by cleaving the peptide bond between Gly 775–Ile 776 or Gly 775–Lys 776 in 
native type I, II or III collagen molecules. 2 Based on domain organization and substrate preference, 
MMPs are grouped into collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT)-
MMPs and others. 3
Table 2.1 List of MMPs. 4
11
Collagenases
Collagenases (MMP-1, MMP-8, MMP-13 and MMP-18) cleave interstitial collagens I, II and III 
into characteristic  3/4 and 1/4 fragments but they can digest  other ECM molecules and soluble 
proteins. Recent studies indicated that MMP-1 activates protease activated receptor (PAR) 1 by 
cleaving the same Arg-Ser bond cleaved by thrombins, which promotes growth and invasion of 
breast  carcinoma  cells.  Two  other  matrixins:  MMP-2  and  MMP-14  (MT1-MMP),  have 
collagenolytic  activity,  but  they  are  classified  into  other  subgroups  because  of  their  domain 
compositions.
Gelatinases
Gelatinases (MMP-2 and MMP-9) readily digest gelatin with the help of their three fibronectin type 
II repeats that binds to gelatin/collagen. They also digest a number of ECM molecules including 
type IV, V and XI collagens, laminin, aggrecan core protein, etc. MMP-2, but not MMP-9, digests 
collagens I, II and III in a similar manner to the collagenases. The collagenolytic activity of MMP-2 
is much weaker than MMP-1 in solution, but because proMMP-2 is recruited to the cell surface and 
activated by the membrane-bound MT-MMPs, it may express reasonable collagenolytic activity on 
or near the cell surface.
Stromelysins
Stromelysins  (MMP-3,  MMP-10  and  MMP-11)  have  a  domain  arrangement  similar  to  that  of 
collagenases,  but  they do not  cleave  interstitial  collagens.  MMP-3 and MMP-10 are  similar  in 
structure and substrate specificity, but MMP-11 (stromelysin 3) is distantly related. The MMP-11 
gene is located on chromosome 22, whereas MMP-3 and MMP-10 are on chromosome 11, along 
with  MMP-1,  -7,  -8,  -12,  -20,  -26  and  -27.  MMP-3  and  MMP-10  digest  a  number  of  ECM 
molecules  and participate  in  proMMP activation.  MMP-11,  on  the  other  hand,  has  very  weak 
activity toward ECM molecules, but cleaves serpins more readily. MMP-11 has a furin recognition 
motif RX[R/K]R at the C-terminal end of the propeptide and therefore it is activated intracellularly. 
An intracellular 40-kDa MMP-11 isoform (β-stromelysin 3) is found in cultured cells and placenta. 
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This transcript, resulting from alternative splicing and promoter usage, lacks the signal peptide and 
the pro-domain. The function of this isoenzyme is not known.
Matrilysins
Matrilysins (MMP-7 and -26) lack a hemopexin domain. MMP-7 is synthesized by epithelial cells 
and is secreted apically. Besides ECM components it processes cell surface molecules such as pro-
α-defensin,  Fas-ligand,  pro-tumor  necrosis  factor α,  and  E-cadherin.  MMP-26  is  expressed  in 
normal cells such as those of the endometrium and in some carcinomas. It digests several ECM 
molecules, and unlike most other MMPs, it is largely stored intracellularly.
MT-MMPs
MT-MMPs in mammals includes four type I transmembrane proteins (MMP-14, -15, -16, and -24) 
and two glycosylphosphatidylinositol-anchored proteins (MMP-17 and -25). They all have a furin 
recognition sequence RX[R/K]R at the C-terminus of the propeptide. They are therefore activated 
intracellularly and active enzymes are likely to be expressed on the cell surface. All MT-MMPs, 
except MT4-MMP (MMP-17) can activate proMMP-2. MT1-MMP (MMP-14) has collagenolytic 
activity on collagens I, II, and III. MT1-MMP null mice exhibit skeletal abnormalities during post-
natal development, which is attributed to the lack of collagenolytic activity.
Seven MMPs are not grouped in the above categories although MMP-12, MMP-20 and MMP-27 
have similar structures and chromosome location as stromelysins. 
Metalloelastase, Enamelysin, Epilysin and other MMPs.
Metalloelastase (MMP-12) is expressed primarily in macrophages, but is also found in hypertrophic 
chondrocytes and osteoclasts. It digests elastin and a number of ECM molecules. It is essential in 
macrophage migration.
MMP-19 digests many ECM molecules including the components of basement membranes. It is 
also  called  RASI  (rheumatoid  arthritis  synovial  inflammation)  as  it  is  found  in  the  activated 
lymphocytes and plasma from patients  with rheumatoid arthritis  and it  is also recognised as an 
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autoantigen in patients with rheumatoid arthritis and systemic lupus erythematosis. It is, however, 
widely expressed in many organs including proliferating keratinocytes in healing wounds.
Enamelysin (MMP-20) is expressed in newly formed tooth enamel and digests amelogenin.
MMP-21 was originally found in Xenopus and more recently in mice and humans. It is expressed in 
various fetal and adult tissues and in basal and squamous cell carcinomas. It digests gelatin, but 
information about the action on ECM components is not known.
MMP-23  is  a  unique  member  as  it  has  unique  C-terminal  cysteine-rich  immunoglobulin-like 
domains instead of a hemopexin domain. The propeptide lacks a cysteine switch. It is proposed to 
be a type II membrane protein having a transmembrane domain at the N-terminal of the propeptide, 
but the enzyme is released from the cell as the membrane anchored propeptide is cleaved by a 
proprotein convertase.
MMP-27 was  first  found in  chicken  embryo  fibroblasts.  Chicken  MMP-27 digests  gelatin  and 
casein and causes autolysis  of the enzyme,  but little  information is  available  on the activity of 
mammalian enzyme.
Epilysin (MMP-28) is expressed in many tissues such as lung, placenta, heart, gastrointestinal tract 
and testis. The enzyme expressed in basal keratinocytes in skin is considered to function in wound 
repair. It is also elevated in cartilage from patients with osteoarthritis and rheumatoid arthritis.
MMP-21, MMP-23 and MMP-28 have a furin recognition sequence before the catalytic domain and 
therefore they are likely to be activated intracellularly and secreted as active enzymes. 3
Interest in MMPs increased in the late 1960s and early 1970s following observations that MMPs are 
up-regulated in diverse human diseases including rheumatoid arthritis and cancer. 
However,  recent  clinical  data  indicate  that  the  relationship  between  MMPs and  disease  is  not 
simple; for example, increased MMP activity can enhance tumour progression or inhibit it.
This complex relationship between MMP expression and cancer has increased the basic and clinical 
interest in understanding MMP function  in vivo, but it has also focused attention on MMPs and 
pathologies.
The activity of MMPs is controlled at many levels and the regulation of their activity remains a 
topic of intense research.
Analysis  of  MMPs  genetic  knockouts  animals  have  offers  opportunities  to  identify  essential 
functions  of  every  single  MMP  and  to  validate  candidate  substrates  by  looking  for  cleavage 
products in the control animal and uncleaved proteins in the mutant animal. 
The initial characterizations have described surprisingly subtle phenotypes, with all MMP knockout 
lines surviving to birth (table 2.2).  5
14
Table 2.2. Relation between MMP-null rats and impaired functions. 5
Main Structure of MMPs
MMPs are members of the metzincin group of proteases, which are named after the zinc ion and the 
conserved Metionine residue at the active site.
The first structure of an MMP in complex with a synthetic inhibitor (MMP-1 catalytic domain) was 
reported by Lovejoy and co-workers. 6 
Mammalian  MMPs share  a  conserved domain  structure (figure  2.1)  that  consists  of  a  catalytic 
domain and an auto-inhibitory pro-domain.
The catalytic activity of MMPs is regulated at four points: gene expression, compartmentalization 
(i.e.,  pericellular  accumulation  of  enzyme),  proenzyme  (or  zymogen)  activation,  and  enzyme 
inactivation and is further controlled by substrate availability and affinity. 7
Most of the matrix metalloproteinases consist of four distinct domains, which are N-terminal pro-
domain, catalytic domain, hinge region, and C-terminal hemopexin-like domain.
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Figure 2.1. MMP domains and activation mechanism. 5
The N-terminal prodomain.
The MMPs are initially synthesized as inactive zymogens with a pro-peptide domain that must be 
removed in order to activate the enzyme.
The prodomain essentially consists of three helices that are arranged nearly perpendicular to each 
other and connected via rather flexible and proteolysis susceptible loops. In case of MMP-1 and 
MMP-2, the loop between helix H1 and helix H2 contains the region of the first activation cleavage. 
This first cleavage is supposed to destabilize the threehelix bundle of the MMP prodomains. 8
The catalytic domain
The catalytic power of MMPs is encoded in four essential structural elements:
1. Binding of the main chain of the substrate in the active site cleft.
2. The specificity subsite pockets that define the active site, in particular the S1' subsite.
3. The zinc ion-binding histidine triad and catalytic glutamate.
4. Binding to secondary substrate sites outside the active site.
The catalytic domain of the MMPs contains two zinc atoms. One of these atoms plays a catalytic 
role and the other a structural role.  The thiol group of the cysteine residue within the propeptide 
coordinates to the catalytic zinc atom and thereby confers latency. This interaction must be broken 
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before the metalloproteinase can degrade matrix proteins. 9 Main chain binding of protein or peptide 
substrates  to  the  active  site  occurs  through formation  of  an  antiparallel  β-sheet  structure,  with 
hydrogen bonds formed between the substrate and enzyme. A polarized water molecule bound to 
the active site Zn2+ ion and general base glutamate residue is essential in catalyzing peptide bond 
cleavage.  In MMPs, the Zn2+ ion is coordinated by the three histidines  in the HExxHxxGxxH 
metzincin signature motif. Mutagenesis of any one of these His residues ablates catalytic activity. 
The nucleophilic attack by the catalytic water molecule in MMPs occurs on the carbonyl  of the 
substrate  scissile  peptide  bond  to  form a  tetrahedral  transition-state  intermediate  in  which  the 
negatively charged oxygen is stabilized by coordination with the catalytic Zn2+ ion. 10
The catalytic domain of all MMPs is similar in showing a shallow active-site cleft notched into the 
front surface and separating the smaller ‘lower subdomain’ from the larger ‘upper subdomain’. This 
cleft extends horizontally across the molecule and would bind a peptide substrate from left to right. 
The upper subdomain encompasses a characteristic five-stranded, highly twisted -sheet, flanked 
by three surface loops on its convex side and by two long regular -helices on its concave side. 
Four of the five -strands are aligned in a parallel fashion, only the cleft-sided ‘edge strand’ IV 
runs in opposite direction. 8
The active site is constituted by specificity subsite pockets that define it:
S1, S2, S3, S4, S1’, S2’, S3’ and S4’ and the substrate posses the corresponding portions named P1, 
P2, P3, P4, P1’, P2’, P3’, P4’ (figure 2.2).
The S1' specificity pocket of MMPs accommodates this side chain and so the size and chemical 
characteristics of the S1' subsite are important in determining peptide bond preference for cleavage. 
For  example,  the  small  hydrophobic  S1'  pocket  of  MMP-1  and  MMP-7  restrains  substrate 
preference to small hydrophobic residues at P1'. In contrast, other MMPs such as MMP-2, MMP-3, 
MMP-8, MMP-9, and MMP-13 have large S1' pockets and can accommodate a more diverse range 
of amino acids at P1'. 9, 10
Figure 2.2. Schematic interactions between MMPs and MMP inhibitors. 11
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The S1’ pocket is relatively deep for most MMP enzymes (e.g., MMP-2, MMP-3, MMP-8, MMP-9, 
MMP-13, etc.), but for certain MMP enzymes (e.g., MMP-1, MMP-7, and MMP-11) it is partially 
or completely occluded due to an increase in the size of the side chain of the amino acid at position 
193 (MMP-8 numbering) from leucine to arginine (MMP-1), tyrosine (MMP-7), glutamine (MMP-
11), or one of the amino acid residues that form the pocket. It has also been shown that the mutation 
of S1’ subunit tyrosine of MMP-7 to leucine changes the substrate specificity to be more like that of 
the deep pocket enzyme MMP-3. Homology models for MMP-2 and MMP-9 based on the structure 
of MMP-3 suggest that there may be differences in the shape of the bottom of the S1’ subunit for 
the deep pocket enzymes.  In the case of MMP-2, the S1’ pocket may be a channel with no bottom, 
whereas that for MMP-9 is said to be a pocket- like subsite. Generally the subunit S2’ is a solvent-
exposed cleft and the S3’ subunit is a really ill-defined solvent-exposed region. 
Substrate selectivity
The preferred amino acid in substrate subunit P3 is proline for all the kinds of examined enzymes. 
Arginine is preferred at P2 for MMP-2 selectivity, whereas Leucine and Methionine are preferred 
for MMP-7. Phenylalanine is preferred over Leucine and Methionine at P2 for MMP-3. Valine at 
P1 results in negligible cleavage for all of the enzymes. At the P1 position, Glutamine provides 
significant cleavage by MMP-7 and MMP-8, and negligible by MMP-1, MMP-2, and MMP-9. At 
P1’, the presence of a Tyrosine residue results in highly selective cleavage by MMP-8 as well as 
Leucine and Methionine appear to be preferred for broad-spectrum cleavage; however, on the other 
hand,  the  phage-displayed  results  suggest  that  Methionine  at  P1’  gives  minimal  cleavage  with 
MMP-7. However, the substrate specificity studies suggest that Phenylalanine at P1’ is preferred for 
cleavage  by MMP-3 over  the other  enzymes,  whereas  the phage-displayed  results  indicate  that 
Phenylalanine at P1’ provides negligible cleavage. It has also been shown that MMP-11 and MMP-
14 cleave substrates containing unusual amino acids with extremely long side chains at their P1’ 
position more efficiently than the corresponding substrates with natural phenylalanine or leucine 
amino  acids.  There  is  a  very  little  selectivity  by  the  various  substitutions  at  P2’  position  and 
generally Tryptophan is preferred for efficient cleavage. The same is true for amino acid changes at 
P3’. 
The S3–S1 subsites from a shallow region bordered on one side by the -strand IV that features a 
hydrophobic proline binding cleft at S3. 
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It is interesting to note that the selective replacement of catalytic zinc of MMP-3 catalytic domain 
with  other  transition  metals  that  are  Co2+,  Mn2+,  Cd2+,  and Ni2+ results  in  the  retention  of 
protease activity. However, substitution of the catalytic metal influences the substrate specificity of 
enzyme, since the active-site geometry is altered and hence affects substrate binding. 9
The hinge region.
The hinge-region in MMPs is a segment of 15–65 amino acids. It is of critical importance for the 
stability of the enzyme and also for the degradation of complex substrates such as fibrillar collagen 
by collagenases which require the concerted action of the catalytic and of the hemopexin domain. 
The hinge region itself contributes to the collagen binding and unwinding and its breakdown.
The structures of human and porcine MMP-1 show an elongated peptide segment which is in close 
contact with the catalytic and the hemopexin-like domain. 
Highly conserved residues for the collagenases in this area are prolines, which are in direct contact 
with the catalytic and the hemopexin domain thus stabilizing the domain arrangement in MMP-1. In 
accordance with these structures, mutagenesis experiments showed an 98.5% drop in activity when 
four prolines in the hinge are replaced by alanines. A single mutation of the central glycine in the 
center of the hinge region of MMP-1 to aspartate also strongly reduces collagenolysis, which might 
be explained by reduced flexibility at this site. 8
The C-terminal Hemopexin domain.
This domain has a beautiful common fold. The overall shape is a squat cylinder comprised of four 
β-sheets each representing a hemopexin module and each forming a blade of the four-bladed β-
propeller structure. Each blade is a twisted four-stranded β-sheet that links to the adjacent blades by 
small connecting strands on the rim of the domain and from a longer loop at the center. Extensive 
packing faces on the blade sides between adjacent modules arrange one next to another in a stable 
configuration. Packing of the wedge-shaped modules also forms a central pore in the domain, in 
which are bound either one or two Ca2+ ions. The central Ca2+ ions in the MMP-2 hemopexin C 
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domain are structurally important—their chelation eliminates heparin and fibronectin interactions. 
Although X-ray crystallography also  showed a  potential  Zn2+ ion binding site  on the  MMP-2 
hemopexin C domain, inductive coupled plasma mass spectrometry analysis did not measure any 
significant  zinc  molar  content  in  a  recombinant  human  MMP-2  hemopexin  C  domain.  The 
hemopexin C domain has homology to the collagen-binding domain of vitronectin (which therefore 
will also likely have domains with a four-bladed β-propeller structure). 10
Regulation of MMP Activity
As for all secreted proteinases, the catalytic activity of MMPs is regulated at four points:
- gene expression
-  compartmentalization (i.e., pericellular accumulation of enzyme)
- proenzyme (or zymogen) activation, and enzyme inactivation
-  substrate availability and affinity. 
Some members,  such as MMP-2, MMP-19, MMP-28, and several  MT-MMPs, are expressed in 
normal tissues, implying a role in homeostasis. However, most MMPs are not expressed in resting 
tissue yet are induced in repair or remodeling processes and in diseased or inflamed tissues. 
The cisteine switch 
Harold Van Wart and Henning Birkdahl-Hansen proposed this process as general and required step 
in the activation of all proMMPs (1990), and they named this mechanism the “cysteine switch”, a 
term that remains valid and widely accepted. In essence, the thiol-Zn2+ interaction can be broken - 
and a latent MMP can gain catalytic activity – by three mechanisms:
- direct cleavage of the pro-domain by another proteinase 
- reduction of the free thiol by oxidants or by nonphysiologic reagents such as alkylating agents, 
heavy metal ions, and disulfides,
- allosteric perturbation of zymogen (Figure 2.5). 
Thiol reduction and allosteric controls would lead to inter or intramolecular autolytic cleavage of 
the prodomain.
An important component of the cysteine-switch mechanism is that the prodomain does not need to 
be  removed  for  a  zymogen  to  acquire  activity;  only  disruption  of  the  zinc-thiol  interaction  is 
absolutely required.
Furin Activation
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Furin is a type 1 membrane serine protease present in the trans-Golgi network.
About one-third of MMPs contain an RXKR or RRKR sequence between the pro and catalytic 
domains, which serves as a target sequence for proprotein convertases or furins. MMPs with such 
cleavage site are processed intracellularly before secretion (figure 2.3).
Figure 2.3. Schematic representation of MMP activation. 7
TIMPs:  the endogenous inhibitors of MMPs.
TIMPs is an acronym that stand for tissue inhibitors of metalloproteinases. 
Four TIMP family members exist: TIMP-1, -2, -3 and TIMP-4. 
Each of their N- and C-terminal domains contains 6 conserved cysteine residues that form three 
disulfide loops. The N-terminal region binds to the MMPs’ catalytic  domain and inhibits MMP 
activity, whereas, the C-terminal region interacts with the the proforms of MMP-2 and MMP-9 C-
terminal  hemopexin  domain to stabilize  the pro-enzyme inhibitor  complex.  TIMP-2 is  the only 
TIMP member that specifically interacts on the cell surface with both MT1-MMP and pro-MMP-2 
in order to facilitate the activation of pro-MMP-2. Thus TIMP-2 is unique due to its functions of 
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MMP inhibitor  and activator.  TIMPs can inhibit  all  active MMPs, however,  not with the same 
efficacy. TIMP-1 preferentially inhibits MMP-7, MMP-9, MMP-1 and MMP-3, whereas, TIMP-2 
inhibit more effectively MMP-2. TIMP-3 can inhibits MMP-2 and MMP-9 among other enzymes 
(ADAMs),  whereas TIMP-4 inhibits  MT1-MMP and MMP-2 catalytic  activity.  TIMPs regulate 
proteolytic activity and all the MMP-mediated activities. 12  
Collagene Hydrolysis: Reaction mechanism
The reaction mechanism for the proteolysis by MMPs has been delineated on the basis of structural 
information and shown in Figure 2.4. It is proposed that the scissile amide carbonyl coordinates to 
the active-site zinc (II) ion. This carbonyl is attacked by a water molecule, which is both hydrogen 
bonded to a conserved glutamic acid (Glu-198 in MMP-8) and coordinated to the zinc(II) ion. The 
water molecule donates a proton to the Glu residue that transfers it to the nitrogen of the scissile 
amide,  which  is  followed  by  the  Glu  residue  shuttling  the  remaining  proton  from  the  water 
molecule to the nitrogen of the scissile amide with resultant peptide bond cleavage. In this process, 
the positively charged zinc(II) ion helps to stabilize a negative charge at the carbon of the scissile 
amide and a conserved alanine (Ala-161 in MMP-8) residue helps stabilize positive charge at the 
nitrogen of the scissile amide.
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Figure 2.4. Mechanism of collagen degradation. 9
MMP of our interest
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Despite the huge amount of metalloproteinases that  have been discovered, we have choose just 
three of them: MMP-2, MMP-9 and MMP-13. 
MMP-2
MMP-2 (gelatinase A, 72-kDa type IV collagenase) is one of the two described human gelatinases 
in the MMP family, named for their ability to proteolytically degrade gelatine (denatured collagen). 
MMP-2 is ubiquitously expressed as a 72-kDa proenzyme and subject to extensive glycosylation. 
Expression  of  MMP-2  is  constitutive  and  most  proinflammatory  stimuli  fail  to  increase  the 
expression  level  since  the  gene,  in  contrast  to  that  of  MMP-9,  lacks  binding  sites  for  pro-
inflammatory transcription factors such as activator protein-1.
The  MMP-2  proenzyme  is  activated  by  forming  a  complex  with  TIMP-2  under  appropriate 
stoichiometric conditions, which in turn is a substrate for the membrane bound membrane type-1 
MMP (MMP-14) that removes the prodomain of proMMP-2 by proteolytic cleavage (aided by free 
active MMP-2), yielding the truncated 64-kDa active enzyme. If the concentration of TIMP-2 is too 
high,  both MMP-14 and active  MMP-2 will  be  inhibited  and no further  activation  will  ensue. 
Besides this activation pathway, proMMP-2 can also be activated by thrombin and activated protein 
C. MMP-2 differs from other MMPs in that the catalytic domain contains cysteine-rich inserts that 
resemble  the  collagen-binding  regions  of  the  type  II  repeats  in  fibronectin.  These  inserts  are 
required for binding and cleavage of collagen and elastin. MMP-2 is capable of cleaving gelatine, 
type I, IV and V collagens, elastin and vitronectin.
Through their  ability  to  degrade  collagen in  the  vascular  basal  membranes,  the  gelatinases  are 
involved  in  neovascularisation  both  under  physiological  conditions  and  in  pathologies  such  as 
tumor metastasis.
The  state  of  activation  seems  to  be  of  crucial  importance  for  the  function  of  MMP-2  in 
angiogenesis. Recent research has demonstrated that the fully mature active form induces apoptosis 
in endothelial cells and inhibits neovascularization, while an intermediate activated  complex with 
MMP-14 enhances cell survival and promotes angiogenesis. MMP-2 can also facilitate migration of 
cells by direct degradation of the basement membrane thus allowing infiltration of, for instance, 
neutrophils  and  lymphocytes,  or  liberation  of  chemoattractants.  This  latter  process,  named 
‘ectodomain  shedding’,  is  an  important  physiological  function  of  the  membrane-bound ADAM 
proteases,  but  has  also  been  described  for  many other  members  of  the  metzincin  superfamily. 
MMP-2 has been known to be involved in both promoting and inhibiting inflammation by liberation 
of pro-inflammatory mediators.
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Interestingly, MMP-2 knockout mice exhibit a normal phenotype under physiological conditions, 
although the animals do show different response patterns upon allergen challenge, which may be 
attributed to disturbance of the important role of clearing immune cells.
These findings indicate that MMP-2 function may be interchangeable with other metalloproteases, 
an hypothesis that is supported by the observation that expression of the second gelatinase, MMP-9, 
is greatly increased in MMP-2 null mice. 13
MMP-9
MMP-9 (gelatinase B, 92-kDa type IV collagenase) was first discovered in neutrophils in 1974. 
MMP-9 is expressed as a 92-kDa proenzyme, which can be activated to the 83-kDa mature enzyme. 
The larger size of MMP-9 relative to MMP-2 can be attributed to a heavily O-glycosylated collagen 
V-like  insert  that  links  the  metalloprotease  domain  to  the  hemopexin-  like  domain.  MMP-9 
activation may be mediated by removal of the prodomain by serine proteases or other MMPs, or 
may be a  direct  response to  oxidative  stress  that  disrupts  the cysteine  switch (as  a matter  this 
particular  MMP can be usefull  as  a  marker  for acute  ischemic  stroke). 14 While  a  considerable 
overlap  exists  in  the  substrates  degraded  by  MMP-2  and  -9,  MMP-9  is  incapable  of  direct 
proteolysis of collagen I.
MMP-9 has been described to release the biologically active form of vascular endothelial growth 
factor (VEGF), which plays an important role in angiogenesis. This process is complemented by the 
direct  proteolytic  degradation  of  vascular  basement  membrane  proteins,  indicating  that  MMP-9 
(even more than MMP-2) may play a crucial role in the formation of new blood vessels.
Interestingly,  the  hemopexin  domain  of  MMP-9  was  reported  to  be  an  inhibiting  factor  in 
angiogenesis  as  demonstrated  by  decreased  invasion  of  glioblastoma  cells  overexpressing  the 
MMP-9 hemopexin domain in a xenograft model.
MMP-9 null mice show decreased fertility,  since MMP-9 is crucial during several stages of the 
female reproductive cycle (implantation of the embryo and remodeling of endometrial tissue that 
occurs  during  the  menstrual  cycle).  Absence  of  MMP-9  also  leads  to  disorders  in  bone 
development,  specifically  delayed  bone  ossification  due  to  insufficient  angiogenesis  in  growth 
plates and reduced osteoclast recruitment.
Whereas MMP-2 is primarily inhibited by TIMP-2, MMP-9 is mostly inhibited by TIMP-1 and 
contrary to MMP-2, which is expressed ubiquitously under physiological  conditions,  MMP-9 is 
increased in malignant cell lines and correlates with their metastatic potential.
The role of gelatinases in pathology has been studied extensively, especially in lung diseases and 
cancer. The amount of both gelatinases in BALF and sputum of patients suffering from chronic 
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asthma  is  higher  than  in  healthy  individuals  and  this  increase  may  be  responsible  for  the 
characteristic  tissue  remodeling  events  observed  in  chronic  asthma  such  as  thickening  of  the 
basement membrane, smooth muscle tissue hypertrophy and reduced epithelial thickness. Presence 
and activity of gelatinases is elevated in many other pulmonary diseases, such as cystic fibrosis, 
bronchiectasis, acute respiratory distress syndrome (ARDS) and infections. 13
MMP-13
MMP-13  (collagenase-3)  is  the  latest  human  collagenase  described  in  literature.  This  enzyme 
exhibits  preference  toward  cleavage  of  type  II  collagen,  effectively  completing  the  substrate 
spectrum of the collagenases. Collagenase-3 was first cloned from breast cancer tissue in 1994. 
MMP-13  expression  can  be  influenced  by  a  wide  range  of  hormones  and  cytokines,  such  as 
parathyroid hormone (indicative of the important role of MMP-13 in bone development), insulin-
like  growth  factors  I  and  II,  platelet  derived  growth  factor,  basic  fibroblast  growth  factor, 
transforming  growth  factor  b1  (interestingly  both  up-  and  downregulates  MMP-13  expression 
depending on the tissue), interleukin-1 and -6, tumor necrosis factor a and many more. ProMMP-13 
can  be  activated  by  auto-proteolysis  or  propeptide  removal  by  various  other  MMPs  like 
stromelysin-1 (MMP-3), yielding a mature enzyme of 48 kDa, which in turn can be inhibited by 
TIMP-1, -2 and -3. Active MMP- 13 is a key factor in the activation pathway of several MMPs. 
Besides the TIMP route of inactivation, MMP-13 can bind to a specific receptor on the surface of 
osteoblasts and fibroblasts resulting in internalization and degradation of the protease.
MMP-13 plays an important role in bone development and remodeling, as may be anticipated from 
its capability to cleave type II collagen (a major component of cartilage).
This  rather  specific  function  is  reflected  in  a  limited  expression  profile  of  MMP-13  during 
development and adulthood, which is restricted to developing skeletal tissue. MMP-13 has, contrary 
to  the other  collagenases,  a  relatively high specific  activity  toward gelatine,  indicating  that  the 
proteolytic  role  of  MMP-13 expands  past  the  first  step  of  cleavage  of  triple-helical  collagens. 
Further identified substrates of MMP-13 include aggrecan and perlecan, transforming growth factor 
, biglycan, the large protein species of tenascin-C, fibrillin-1 and -2, fibrinogen and two serpins 
(a2-antichymotrypsin  and  plasminogen  activator  inhibitor-2).  MMP-13  expression  has  been 
regularly  referred  to  in  the  literature  as  indicative  of  various  cancerous  processes  including 
chondrosarcoma, breast cancer, head and neck tumors and melanoma. In all cases, high expression 
of MMP-13 seems to be related to
aggressiveness of the tumor, and MMP-13 may even be required for metastasis of certain tumors as 
demonstrated for malignant melanoma. Regarding the important role of MMP-13 in bone turnover, 
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it is not surprising that this enzyme has been linked to various bone-related diseases. Since MMP-
13 degrades  both  type  II  collagen  and aggrecan,  it  has  been  linked  to  cartilage  destruction  in 
rheumatoid and osteoarthritis. The specialized role of MMP-13 in bone development and disease 
has made it an attractive target for selective MMP-13 inhibitors as therapeutic compounds. 13
MMPs and cancer
MMPs have a relevant role in the pathophysiology of diseases suchas arthritis, multiple sclerosis, 
periodontal  disease,  atherosclerosis,  and  cardiac  injury and remodeling.  15 A number  of  cancer 
studies have correlated MMP expression and disease outcome.
MMPs can contribute to tumor growth not only by degradation of the extracellular matrix (ECM) 
but  by the  release  of  sequestered  growth factors  or  the  generation  of  bioactive  fragments.  For 
instance,  MMP-9  mobilizes  VEGF  from  the  ECM  and  cleaves  type  IV  collagen  to  generate 
tumstatin,  an angiogenesis  inhibitor.  MMPs are also important  in tumor progression,  promoting 
invasion, immune escape and many other events. However, particularly in carcinomas, MMPs are 
associated  with  the  supporting  ‘host’  cells  rather  than  the  tumor  cells  and  this  finding  has 
emphasized the emerging theme of the importance of the microenvironment in tumorigenesis. 
MMP-12, MMP-13 and cathepsin K showed an increase expression in human tumors compared 
with normal lung. Immunohistochemical analysis also confirmed MMP-12 expression in the stroma 
of human lung tumor samples.
It is notable that animal studies have shown that MMPs sometimes have ‘protective’ roles in cancer 
development. Mmp8-null male or ovariectomized female mice develop significantly larger numbers 
of skin papillomas after a chemical carcinogen treatment and higher grade and more aggressive skin 
tumors developed in Mmp9-null mice. In a human study of MMP-12 in squamous cell carcinoma it 
was found that high expression in tumor cells was associated with more aggressive tumors and high 
expression in tumor macrophages was correlated with lower grade tumors. 
It is possible that obtaining a detailed understanding of the potential role of MMPs in the different 
cell types associated with tumors may be vital for the design of therapeutic anti-MMP strategies.16
Regulation of angiogenesis
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MMPs also have complex roles in angiogenesis. It is known that MMPs can promote endothelial 
cell  migration  and  trigger  angiogenic  switch.  For  example,  MMP-9  participates  in  switching 
angiogenesis by releasing VEGF from ECM. Also, MMP-2 activity was suggested to be necessary 
for  the  switch  to  angiogenic  phenotype  in  an  animal  model.  Furthermore,  MMPs increase  the 
bioavailability of the pro-angiogenic growth factors, vascular endothelial  growth factor (VEGF), 
fibroblast growth factor- 2 (FGF-2), and TGF-, which stimulate proliferation and migration of 
endothelial cells. MT1-MMP regulates VEGF-A expression by promoting VEGFR-2 cell surface 
localization  thereby  activating  VEGFR-2-Src-Akt-mTOR  pathway.  MMP-7  degrades  soluble 
VEGF receptor-1 (sVEGFR-1/sFlt-1), an endogenous VEGF inhibitor that sequesters VEGF and 
blocks its access to VEGF receptors. The degradation of sVEGFR-1 then liberates VEGF from the 
endogenous trap and allows its access to membrane receptors on endothelial cells. However, MMPs 
may have adverse effects on angiogenesis. For example, MT1- MMP-mediated endoglin shedding 
inhibits tumor angiogenesis. The generation of angiostatin and endostatin, two potent angiogenesis 
inhibitors, also involves MMPs.
MMP-7 and MMP-9 hydrolyze plasminogen to generate angiostatin fragments. Endostatin is the C-
terminal proteolytic product of the collagen XVIII a1 chain and MMP-14 can cleave collagen XVIII 
to  generate  endostatin-spanning  fragment.  Hence,  we  speculate  that  the  effects  of  MMPs  on 
angiogenesis may be context-dependent. The outcome relies on the availability of specific MMPs 
and the balance between two opposing effects of individual MMPs on angiogenesis. 4
MMP Inhibitors
As described above, matrix metalloproteinases are involved in the regulation of the cellular turnover 
and in the spreading of metastasis, and their regulation should be a very usefull weapon for fight 
cancer.
Both small molecules (synthetic and natural products) and macromolecular endogenous inhibitors 
have been considered as potential therapies for diseases in which excess MMP activity has been 
implicated.
A tetracycline derivative, doxycycline (Periostat; CollaGenex Pharmaceuticals Inc., Newtown, PA, 
USA), is currently the only MMPI approved by the U.S. FDA and is used as an adjunct therapy in 
adult periodontitis. One of the main reasons for the limitations of hydroxamate-based inhibitors is 
due to its poor bioavailability and the toxicity arising from its metabolic stability limitations (the 
amide  bond can  be  easily  hydrolyzed  with  formation  of  hydroxylamine  and the  corresponding 
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carboxylic  acids).  On the other  hand,  most  of  the inhibitors  tested  were broad-spectrum MMP 
inhibitors that make no distinction between these enzymes. 17
Many inhibitors have been developed either by pharmaceutical companies and academies. 
Most MMP inhibitors (MMPi) are constituted from a functional groups which are capable to form 
H bonds with the structure enzyme and one or more residues that can interact through Wan der 
Waals interactions with the enzyme subsite and a zinc-binding group (ZBG), which is deputate of 
the catalytic Zn2+ chelation. The most common moiety used for the synthesis of sudden inhibitors 
are  hydroxamates,  carboxylates,  phosphinates  and barbituric.  The  ZBG however  is  not  always 
present, especially in the most recent and innovative inhibitors.
MMPsI can be classified in peptidomimetics and not peptidomimetics. 
Either peptidomimetics and not peptidomimetics can be classified for their ZBG moiety.
Here under will be report the most important and innovative class of inhibitors.
Hydroxamates.
The hydroxamate  is  the  most  common and the  most  powerful  moiety  for  the  chelation  of  the 
catalytic zinc, it acts as a bidentate ligand and it’s widely used for the developmental of MMPsI. 
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Figure 2.5. Hydroxamate chelation mechanism. 18
Efficiency of hydroxamates is supported by good in vitro activity data and a very huge amount of 
good selective nanomolar inhibitors have been synthesised, but unfortunately have result in a fail in 
clinical trials.
The failure of hydroxamic acid based MMPi at a clinical level may stem, in part, from the lack of 
selectivity  of  hydroxamic  acids  towards  the  Zn2+ ion,  poor  pharmacokinetics,  and  poor  oral 
bioavailability.
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Consequently, some efforts have been made to identify alternatives to the hydroxamic acid ZBG. In 
most  of  these  studies  there  have  been  only  a  comparison  between  hydroxamic  acids  and  the 
corrisponding carboxylic  acids  (usually  the  synthetic  precursor  of  most  hydroxamic  acids)  and 
generally  a  loss  in  potency has  been  observed  likely  due  to  the  change  in  binding  mode  and 
diminished donor ability of the carboxylate ligand. 
Castelhano and co-workers reported the selectivity and potency of MMPi with several  different 
ZBGs  such  ’reverse’  hydroxamates,  carboxylates,  thiols  and  phosphinates  on  a  common 
indolactam/isobutyl backbone moiety. 
As a result of these studies, the use of ZBGs other than a hydroxamate, resulted in a 10- to 250-fold 
loss in potency, but generally no changes in selectivity based on the nature of the 
ZBG. 15 Here under are report two of the most important MMP inhibitors that must be considered in 
this class as broad-spectrum MMPsI:
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Scheme 2.6. Molecular structure of Batimastat and Marimastat.  
Unfortunately these two MMPsI failed during clinical trials due to muscolo-skeletal toxicity.
Pirones
A 2008 paper 15 report an interesting MMP inhibitory activity of some pirone based molecules. 
Docking representation show the chelating effect of pyrone ring over zinc ion (figure 2.7).
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Figure 2.7. Pirone based scaffold in MMP-3 active site. 11
X-ray structures of thiomaltol and maltol tris(pyrazolyl)borate zinc(II) complexes reveal that the 
hydroxythiopyrone and hydroxypyrone ligands coordinate to tris(pyrazolyl) borate zinc(II) in 
different geometries (Fig. 3),12 suggesting that substituents at the same positions of thiopyrone and 
pyrone rings may interact with MMP active sites in different fashions. These findings promote us to 
investigate 5- and 6-substituted hydroxypyrones and hydroxythiopyrones. 11
Figure 2.8. Geometries of maltol- and thiomaltol-tris(pyrazolyl)borate zinc(II) complexes. 11
Barbiturates.
In 2001, following a random screen for anti-tumour agents, workers from the Hoffman La-Roche 
company reported a surprising discovery: certain 5,5-disubstituted pyrimidine-2,4,6,-triones
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(barbiturates)  are  inhibitors  of  the  MMPs with  good gelatinase  selectivity.  This  kind  of  MMP 
inhibitory with barbiturate-based scaffold are without the sedative effects of the classical agents, 
and impart a better in vivo stability respect to other zinc binding group (e.g., hydroxamates).
The ionised barbiturate ring chelates the zinc atom in a tridentate way directing the 5-substituents 
into  the  S1  and  S2  substrate  binding  pockets.  The  class  exhibit  broadly  similar  SAR to  non-
barbiturate  MMP inhibitor  families.  The 5-aromatic  substituents  (biphenyl  or phenyloxyphenyl) 
bind in the deep hydrophobic S1 substrate pocket.  The second 5-substitutent  is  directed in this 
arrangement into the S2 pocket towards solvent. Several elegant studies have demonstrate that C5- 
piperazine  or  piperidine  substitution  is  favourable  for  high  potency  and  moreover  that  the 
heterocycle  imparts  flexibility  in  the  design  of  a  range  of  barbiturate-  based  pharmacological, 
clinical and biochemical tools.
The  structural  basis  for  barbiturate  interactions  with  the  MMPs was  revealed  in  several  X-ray 
studies. 19
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Figure 2.9. (a) Barbiturate inhibitor RO-206-0222 (b) Interaction between inhibitor and active site region of 
MMP-9. Ionic bonds to the catalytic zinc and intermolecular hydrogen bonds are shown as broken lines 
(distances in Å). 20
MMP inhibitors without a zinc-binding group
High-throughput  screening  of  chemical  libraries  has  led  to  the  discovery  of  unusual  MMP 
inhibitors, especially for MMP-13. Among these, MMP inhibitors with no zinc-binding group that 
do not engage in direct interactions with the zinc active site ion has emerged. These compounds 
without the zinc tether can be tailored to target the depth of the MMP S1’ cavity keeping a reduced 
molecular weight, in contrast to inhibitors containing a zinc-binding group. The first highly potent 
and selective inhibitor of MMP-13 reported was compound 1 (Ki = 8 nM towards MMP-13 and no 
activity detected against MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -14 and -16 when tested at 100 
M). The particular binding mode of 1 in MMP-13 active site is illustrated by comparing the X-ray 
structure of MMP-13 in interaction with compounds 1 and 2 (for chemical structures see Scheme 3 
and 2 respectively). Compound 8 binds in the bottom part of the S1’ cavity of MMP-13 and extends 
into an additional cavity termed the “S1’ side pocket” as depicted in figure 2.10.
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Figure 2.10. Superimposition and comparison of cartoon representations of two crystal structures of MMP-
13 in complex with a non-chelating inhibitor 1 (pink stick, PDB code: 1XUD) and with a pyrimidinetrione 
inhibitor 2 (yellow stick, PDB code: 1YOU) illustrating the different S1’ loop conformation and orientation 
of Lys249 in the two complexes. 21
An excellent paper published from Gao et all. of Boehringer Ingelheim Pharmaceuticals 22, report a 
library of compounds born from the same scaffold. Some of them show a very good activity joined 
to an exceptional selectivity for MMP-13. Here is report the main structure of sudden inhibitors.
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Figure 2.11. Main scaffold of selective MMP-13 inhibitors without zinc-binding group SAR studies of 
non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability. 22
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CHAPTER 3
             
            Developmental of Matrix 
Metalloproteinases Inhibitors
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Benzo[d]isothiazol-3(2H)-one-1,1-dioxide Derivatives
I started my research program designing and synthesizing novel MMP-inhibitor (MMPI) candidates 
bearing a benzo[d]sothiazole heterocyclic core, developed as constrained analogues of the known 
sulphonamido-based non peptidic MMPIs of the literature.
Carrying out a throughout literature survey, I realized that the presence of a sulphonamide moiety in 
the non peptidic MMPIs scaffold often plays a pivotal role in allowing the compound to interact 
suitably with the protein binding site. As evidenced in the following Table (Table 1), a number of 
potent and effective MMPIs exploit this group as the key fragment of their templates.
Table 3.1. MMP-Inhibitors characterized by a sulphonamide moiety
Inhibitory Activity (IC50, nm)
Inhibitor name MMP-2 MMP-9 MMP-13
O
O2 S
N
HOHN
O
N
CGS 27023A1 20 9 --
O2 S
N
OHOHN
O Compound 1
3 12,46 12.4
O2 S
N
OHOHN
O Compound 2
2 590 2.44
S
O O
O
O
CF3
N
O
O
HO
H
O
ABT-5183 0.61 0.32 --
It has been pointed out in many studies that a co-occurrent presence of a sulphonamide group and a 
zinc  binding  group,  on  the  same  heterocyclic  scaffold,  may  promote  a  strong  and  effective 
coordination of the catalytic zinc ion within the MMP active site. 
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Literature  examples  clearly  demonstrate  that  the  sulphonamide  group  of  the  inhibitor  may  be 
involved  in  strong hydrogen  bonds  with  amino  acid  residues  from the  active  site  cleft  of  the 
enzyme, thus stabilizing considerably the enzyme-inhibitor adduct. 
The sulphonamide group does not participate in hydrogen bonds, but may enhance the participation 
of the two oxygen atoms, by donating them a major share of the lone pairs of electrons, to form 
coordinating bonds. This lead to the development of partial negative charges on the oxygen atoms, 
to the extent they attract lone pairs from the sulphur atom, turning out able to form hydrogen bonds. 
The strength of this latter clearly depends on the partial negative charges developed on the oxygen 
atoms.
Regarding  the nitrogen atom,  adjacent  to  the sulphur  one,  it  has  a  free  lone  pair  of  electrons. 
Accordingly,  it  can  be  assumed  to  participate  in  some  change-transfer  phenomenons  with  the 
enzyme,  acting  either  as a donor or as an acceptor  of charges,  depending upon the positive or 
negative charge.
A positive  one  implies  that  the  nitrogen  is  acting  as  an  acceptor,  so  that  its  ability  to  donate 
electrons decreases, decreasing the strength of charge transfer phenomenon.
A negative charge,  on the other hand,  means  that  the nitrogen would act  as a donor so that  it 
becomes more capable of donating electron, resulting in stronger charge-transfer phenomenon.
The sulphonamide moiety of the non peptidic MMPIs may not only be exploited to anchor the 
backbone of the protein through hydrogen bonds, but also used to direct properly the hydrophobic 
substituent of the MMPI to the S1’ pocket of the enzyme, thus enabling it to plunge in deeply.
This is clearly emphasized by Ohtani and co-workers, who developed a number of sulphonamido 
and carboxamido derivatives as effective inhibitors of type IV collagenases, MMP-2 and MMP-9.7
As schematically represented in Figure 3.1, the C-N-S-C fragment, representing the sulphonamide 
portion  of  the  2-(biphenyl-4-ylsulfonamido)-N-hydroxy-3-phenylpropanamide,  3,  adopts 
exclusively  a  gauche  conformation,  thus  allowing the  biphenyl  substituent  of  the compound  to 
direct properly toward the S1’ pocket.
On the contrary, when the same fragment is replaced by the C-N-(C=O)-C portion, as in the N-(1-
(hydroxyamino)-1-oxo-3-phenylpropan-2-yl)biphenyl-4-carboxamide,  4, the torsion adopts a trans 
conformation, thus directing the biphenyl substituent to the shallow S2’ and S3’ subsites. Such a 
change heavily affects the inhibitory efficacy of the resulting compound. Actually, while compound 
3 proves to inhibit potently both MMP-2 and MMP-9, showing IC50 values in the low micromolar 
range, derivative 4 turns out rather ineffective (Figure 1).
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Figure 3.1. Schematic interaction of the sulphonamido and carboxamido inhibitors 3 and 4.
Tetrahedral  geometry at  the sulphur  atom, as opposed to  planarity of the carboxamide linkage, 
provides ideal geometry to link S1’ directed hydrophobic substituent with ZBG.
Elongation of the sulphonamide substituent reduces the inhibitory activity against enzymes with 
shallower S1’ pocket,  mainly MMP-1 and MMP-7, while retains efficacy against enzymes with 
open S1’ pockets, such as MMP-2, -8 and -13, and consequently enhances the selectivity.
Therefore,  the  sulphonamide  substituent  can  be  profitably  manipulated  somehow  to  alter  the 
selectivity pattern of the resulting compounds.4, 5
Intrigued by the biological versatility of the sulphonamide portion, I focused my attention on the 
benzo[d]sothiazole  heterocyclic  core,  in  which  this  key  fragment  is  constrained  into  a  five 
membered  skeleton.  Aiming  to  disclose  novel  hits,  to  develop  as  MMPI leads,  I  explored  the 
versatility  of  this  scaffold  designing  and synthesizing  a  number  of  derivatives,  summarized  in 
Figure 3.2.
R2 S
N
O
O
O
R1
R1: H, (CH2)nCOOH
R2: H, NHCOCH3, NHCOC6H5, NHCOC6H4-p-X 
n: 1-3
Figure 3.2. General formula of benzo[d]isothiazole MMPIs
At first, to investigate a possible role of the sulphonimido moiety as distinctive ZBG, only alkyl- 
and aryl-amido substituents were inserted in the position 6 of the heterocyclic scaffold. Later, to 
verify  any  cooperation  between  the  sulphonimido  moiety  and  a  well-known  ZBG,  carboxylic 
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O
residues of different length were inserted in the position 2 of the core. Finally, both the substitution 
patterns were explored.
The  novel  benzisothiazole  derivatives  were  prepared  from the  key  intermediate  5,  6-nitro-1,2-
benzisothiazol-1,1-dioxide-3(2H)-one,  which  were  synthesized  following  a  previously  reported 
procedure6 (Scheme 3.3).
O2N
CH3
O2N
CH3
O2NS
Cl
O O
O2N
CH3
S
NH2
O O
S
NH
O
O
O
ClSO3H NH4OH CrO3
56 7 8
Scheme 3.3. Synthetic Pathway of 6-nitro-1,2-benzisothiazol-1,1-dioxide-3(2H)-one.
Reaction  of  the commercially  available  4-nitrotoluene,  6,  with  chlorosolfonic  acid  afforded the 
corresponding sulphonil chloride, 7. Treatment of 7 with concentrated ammonium hydroxide led to 
the sulphonamide 8. Cyclization of 8, by means of oxidation of benzylic carbon to carboxylic acid 
with chromium trioxide, afforded the target 6-nitro-1,2-benzisothiazol-1,1-dioxide-3(2H)-one, 5.
To obtain MMPI hits 10 a-c, bearing different substituents in the position 6 of the nucleus, the key 
intermediate  5 was reduced to the corresponding amino derivative,  9,  at  room temperature and 
atmospheric pressure, via a catalytic hydrogenation performed in the presence of Palladium/Carbon 
as the catalyst. Compound 9 gave the target hits, 10 a-c, by reaction with the suitable acyl chloride, 
in the presence of Et3N and DMAP (Scheme 3.4).
NH
O
Pd/C, H2
EtOH
NH
O
R Cl
O
PhMe/Et3N/DMAP
NH
O
SSS
O O O O O O
O2N H2N N
H
5 9 10 a-c
R
O
a:  R = CH3
b:  R = C6H5
c:  R = C6H4-p-OCH4
Scheme 3.4. Synthetic Pathway to obtain MMPI hits 10 a-c.
Scheme 3.5 describes the synthetic pattern employed to obtain inhibitors bearing a carboxylic group 
in the position 2 of the core. 
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Scheme 3.5. Synthetic Pathway to obtain MMPI hits 13 a-c.
Reaction  started  with  the  commercially  available  1,2-benzisothiazol-1,1-dioxide-3(2H)-one,  11, 
which  was  first  converted  to  the  corresponding  sodium  salt,  through  treatment  with  sodium 
ethoxide, than alkylated with the suitable alo-esters, with a number of carbon atoms ranging from 
two to four, to give compounds  12 a-c. Finally, the hydrolysis of the ester group, to achieve the 
target  acids  13  a-c,  was  performed  with  sodium  hydroxide  in  methanol/water,  followed  by 
acidification with diluted hydrochloric acid.
Compounds substituted in both positions 2 and 6 of the benzisothiazole scaffold were synthesized 
as depicted in Scheme 3.6.
6-Nitro-1,2-benzisothiazol-1,1-dioxide-3(2H)-one,  5,  was converted to the corresponding sodium 
salt, then alkylated with ethyl bromoacetate to obtain the ester  14. Catalytic hydrogenation of the 
nitro  group  afforded  the  amino  derivative  15,  which  gave  the  6-substituted  esters,  16  a,b,  by 
reaction with the suitable acyl chloride in the presence of triethyl amine and DMAP. Hydrolysis of 
the ester group, realized with sodium hydroxide in methanol/water, followed by acidification with 
diluted hydrochloric acid, gave the target MMPI hits 17 a,b.
NH
O
1) EtONa/EtOH
N
O
SS
O O O O
COOEt
5 14
2) ClCH2COOEt
H2, Pd/C
R Cl
O
PhMe/Et3N/DMAP
N
O
S
1) NaOH
2) HCl
OO
HN
R O
COOEt
O2N O2N
EtOH
N
O
S
O O
COOEt
15
H2N
16 a,b
N
O
S
OO
HN
R O
COOEt
17 a,b
Scheme 3.6. Synthetic Pathway to obtain MMPI hits 17 a,b.
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All the novel hits were tested for their inhibitory activity and selectivity against specific MMPs, 
namely MMP-2, MMP-9 and MMP13. Assays were performed by the research group of Professor 
Armando Rossello, serving at our Faculty, exploiting a fluorescent method. Biological results are 
reported in Table 2 and expressed as IC50.
All the synthesized compounds showed IC50 values in the high micromolar range, thus turning out 
as novel and exploitable MMPIs hits.
Products  10 a-c,  characterized by the presence of the sulphonimido moiety as distinctive ZBG, 
showed  the  best  inhibitory  activity.  On  the  contrary,  the  insertion  of  an  additional  carboxylic 
moiety, as in  13 a-c, determined a reduction of efficacy,  more marked for the propionic and the 
butyric residues.
Table 3.2. Inhibitory activity of MMPI hits 10 a-c, 11, 17 a,b and 13 a-c.
N
O
S
O O
R1
R
IC50 (M)
N R R1 MMP-2
MMP-
9
MMP-13
11 H H 338 290 511
10a* H NHCOCH3 120 69 85
10b* H NHCOC6H5 190 125 ---
10c* H NHCOC6H5-4-OCH3 360 --- ---
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13a CH2COOH H 190 250 230
13b CH2CH2COOH H 614 249 485
13c CH2CH2CH2COOH H 545 274 443
17a* CH2COOH NHCOPh 298 260 210
17b* CH2COOH NHCOC6H4-4-Cl 280 195 422
* Previously synthesized by Sartini et all.
Values  suggest  that  the  only  appreciable  increase  in  activity  is  observable  in  compound  N-
acetylated with un-alkylated imidic position (10a).
This has lead us to develop another series of compound with a very similar scaffold but without the 
solfonimidic function in order to evaluate the importance of the latter.
As a matter of fact phtalimide is closely related and the corresponding 5 and 6 nitro derivatives are 
commercially available.
The synthetic protocol used remained the same, no different conditions were used for the synthesis 
of the phtalimidic derivatives.
Isoindoline-1,3-dione Derivatives
Moving from the previously developed MMPIs, I planned to remove the sulphonimidic function, in 
order  to  evaluate  its  importance  for  a  fruitful  interaction  with  the  enzymes’  binding  site. 
Accordingly,  a  number  of  isoindoline-1,3-dione  derivatives  were  synthesized,  summarized  in 
Figure 3.7.
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R:  H, (CH2)3COOH
R1: NHCOC6H5, NHCOCH2C6H5
Figure 3.7. General formula of isoindoline-1,3-dione MMPIs
The  novel  compounds  were  easily  synthesized  from  the  commercially  available  4-  and  5-
nitroisoindoline-1,3-diones, following the synthetic pathways reported in Schemes 1 and 2.
To obtain derivatives 20 a-d, bearing an acyl amino substituent either in position 4 or in position 5 
of the core, compounds 18 a,b were first converted to the corresponding amino-isoindolines, 19 a,b, 
by a catalytic hydrogenation performed in the presence of Palladium/Carbon as the catalyst, than 
treated with the suitable acyl chloride in pyridine (Scheme 3.8).7
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1 8  a,b
a: 4 -NO2
b: 5 -NO2
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1 9  a,b
a: 4 -NO2
b: 5 -NO2
Pd /C, H2
EtOH
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O
Py, r.t.
HN N
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O
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O
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20  a-f
a: 4 -NHCOC6 H5
b: 4 -NHCOCH2 C6 H5
c : 5 -NHCOC6 H5
d: 5 -NHCOCH2 C6 H5
e : 5 -NHCOC6 H4 -p -Cl
 f: 5 -NHCOC6 H4 -p -C6 H5
Scheme 3.8. Synthetic Pathway to obtain MMPI hits 20 a-f.
Inhibitors characterized by the presence of a carboxylic function, 24 a,b were prepared as depicted 
in Scheme 3.9. The starting material,  18b, was first alkylated to the corresponding ester,  21, than 
reduced to the 5-amino derivative 22. Reaction with the suitable acyl chloride, in pyridine7, gave the 
acylamino esters  23 a,b, which were hydrolized to the desired inhibitors  24 a,b through reaction 
with sodium hydroxide in methanol/water, followed by acidification with diluted hydrochloric acid.
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Scheme 3.9. Synthetic Pathway to obtain MMPI hits 24 a,b.
All the novel compounds were tested for their ability to inhibit MMP-2, MMP-9 and MMP-13. 
Results obtained are reported in the following Table (Table 1), expressed as IC50 values. Similarly 
to what observed for the benzisothiazole derivatives, the insertion of a well-known ZBG on the 
heterocyclic core turned out detrimental for the biological efficacy, as compounds 24 a,b, bearing a 
butyric chain, showed the lowest activity.
Otherwise, isoindolinone inhibitors showed an appreciable efficacy, more marked for compounds 
20c and 20f, bearing respectively a benzoylamino and a 4-phenylbenzoylamino substituents in the 
position 5 of the heterocyclic core.
Table 3.3. Inhibitory activity of MMPI hits 20 a-f, and 24 a,b.
45
R2 N
O
R1
O
IC50 (M)
N R1 R2 MMP-2
MMP-
9
MMP-13
20a H 4-NHCOC6H5 … 181 130
20b H 4-NHCOCH2C6H5 232 120 181
20c H 5-NHCOC6H5 … 59 16
20d H 5-NHCOCH2C6H5 … … >200
20e H 5-NHCOC6H4-p-Cl 244 … 220
20f H 5-NHCOC6H4-p-C6H5 116 93 63
24a CH2CH2CH2COOH 5-NHCOC6H5 450 590 620
24b CH2CH2CH2COOH 5-NHCOCH2C6H5 380 500 530
Going  on  with  my  studies  on  the  isoindolinone  derivatives,  I  considered  the  opportunity  to 
substitute the imidic proton of the core with an hydroxy group. 
The rational explanation consists in the well documented chelating capacity of a particular moiety 
extensively used for synthesis of MMPs inhibitor: hydroxamate. Numerous synthetic protocols are 
available in literature for the synthesis of these compounds, but a great disadvantage is the intrinsic 
toxicity due to the metabolic hydrolysis of hydroxamate as a matter small amount of hydroxylamine 
are liberated in-situ leading to unwanted dangerous side-effect.
An hydroxy moiety, bound to the imidic nitrogen, could be able to mime the chelating effects of an 
hydroxamate with the advantage of a major stability in a biological environment.
I developed a synthetic pathway which allowed to replace the imidic hydrogen with an hydroxy 
moiety,  while  the isoindolinone nucleus is  conserved either  for synthetic  facilities  or the better 
activities as the IC50 values shown. 
In the following Scheme (Scheme 3.10) the synthetic pathway for the manufacture of  N-hydroxy 
phtalimides is depicted. 
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Scheme 3.10. Synthetic Pathway to obtain MMPI hits 28 a-c.
Di t-butyldicarbonate was used for N protection of 5-nitrophtalimide.8 Nitro group was catalytically 
reduced and consequently acylated with the corresponding acyl  chloride.7 N-hydroxy group was 
introduced through treatment of 27 a-c with a 50% hydroxylamine watery solution in acetonitrile.8 
The biological efficacy of the novel synthesized compounds is reported in Table 3. Derivatives 28b 
and 28c showed appreciable inhibitory properties, above all against MMP-13.
Table 3.4. Inhibitory activity of MMPI hits 28 a-c.
N
O
O
R
OH
IC50 (M)
N R MMP-2
MMP-
9
MMP-13
28a NHCOC6H5 … … 250
28b NHCOC6H4-p-Cl 113 116 73
28c NHCOC6H4-p-C6H5 98 390 72
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Thiazolidinedionic and thiohydantoinic core-based MMPs 
inhibitors:
Synthetic pathways, results and consideration.
Compounds  29 and  30 respectively was promising lead compounds with a tiazolidinedionic and 
thiohydantoinic  core  adviced  from  University  of  Napoli  as  zinc-chelating  non-hydroxamate 
inhibitors of MMPs (Table 3.5).
The carboxylate moiety is directly linked to a thiazolidindione nucleus by a propyl-linker while in 2 
an oxymethylene link the carboxylate group to a benzene. These compounds are characterized by a 
small number of rotatable bonds, indeed this rigidity allows the proper orientation of the ZBG for 
chelate the catalytic zinc ion and the adjustment of P1’ group into the S1’ pocket. 
The thin olefinic chain ending with a phenyl ring gave to compound 1 a good selectivity on MMP-
2.
On computational  chemists  suggestions,  some modification  was  necessary  in  order  to  increase 
efficacy of sudden compounds.
Table 3.5. Lead compounds from University of Napoli.
Chemical
Structure
IC50
MMP-13
(μM)
N
S
O
O
OH
O
a) 29
22
O
HO
O
NH
H
N S
O
b) 30
14
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Modification on butyric acid chain of thiazolidinedionic compounds.
In the following scheme are depicted the variation on the  position of the butyric  acid chain 
suggested from computational studies on lead compound 1 (Scheme 3.11).
Scheme 3.11. Compounds derived from lead molecule.
In scheme 3.12 the synthesis for the creation of the  substituted butyric acid is report:
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RRR
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Scheme 3.12. Synthesis of -benzyl- -bromo butyric acid.
A Wittig reaction took place between phosphor ylide of butyrolactone  33  9 and benzaldehyde or 
phenyl acetaldehyde to obtain respectively 34a or 34b after flash chromatography purification.10
Catalytic reduction of insaturated compound is accomplished with Pd/C mediated hydrogenation, 
and the lactonic ring opening has been conducted with hydrobromic acid in glacial acetic acid. 10 
Esterification took place through the acyl chloride intermediate.
Then  metyhl  α -benzyl -γ -brome  butyrate  and  Methyl  α -phenylethyl  -γ -brome  butyrate  was 
obtained in a good overall yield.
S
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O
31b
MT-060
S
N
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O
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O
31a
MT-066
Then  cynnamilidenthiazolidinedione  core  was  synthesized  through  a  Knovenagel  condensation 
refluxing thiazolidinedione and cynnamaldehyde in a mixture of acetic acid and sodium acetate to 
afford compound in 38 prevalently in Z form (Scheme 3.13). 11
O S
H
N OO
EtOH, Pip e rid in e
re flux
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O38
Scheme 3.13. Cynnamilidenthiazolidinedione core.
Sodium salt  of  sudden  heterocyclic  compound  was  obtained  in  DMF with  the  aim of  sodium 
hydride, then after addiction of ester 37a or 37b the mixture was left stirring at room temperature 
overnight.  Compounds  39a and  39b were  obtained  in  good  yield  and  purified  through  flash 
chromatography.
Hydrolysis was achieved heating 39a or b in a mixture of acetic and hydrochloric acid in a sealed 
tube. 11
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Scheme 3.14. Synthesis of MT- 060.
A saturated analogue was synthesize in order to comparate inhibitory activity and evaluate the 
relevance of double bond in thiazolidinedionic compounds (scheme 3.15, compound 42).
S
N
COOEtO
O
Pd /C H2
EtOH S
N
COOEtO
O
S
N
COOHO
O
Ac OH/ HCl
42
40 41
Ph Ph
Ph
Scheme 3.15. Hydrogenated analogue 42.
Inhibition activity are report in following the following table.
Table 3.6. IC50 of the synthesized inhibitors.
IC50 (µM)
Compd MMP-1 MMP-2 MMP-3 MMP-9 MMP-13 MMP-14
29
N
S
O
O
OH
O
93±8 2.7±0.2 110±26 - 22±0.6 21±2
31a
N
S
O
O
OH
O
50±6 3.6±0.4 35±3.6 8.3±0.9 15±1.2 17.8±1.9
31b
N
S
O
O
OH
O
127±10 2.5±0.3 75±12 16±1.9 13±0.9 29±1.5
42 - - - - 68±5.3 -
NS
O
O
OH
O
IC50 values only slightly lower after this  substitution and other designed analogues with chain 
elongation  have  been  discharged,  however,  the  difference  in  activity  between  hydrogenated 
compound 42 and other unsaturated inhibitors has lead us to the consideration that a rigid carbon 
chain is necessary for increase in the activity.
However the IC50 of  31a and  31b  wasn’t very good, so we have ask ourselves if activity of an 
enantiomer could be better than that of racemic mixture.
Literature report better IC50 regard (R) enantiomer of some MMP inhibitors, so the presence of a 
chiral center on the butyric chain lead us to synthesize and to evaluate the IC50 values of the two 
enantiomers. 2
A stereoselective synthesis  was developed for the obtainment  of the optically active methyl  -
benzyl--iodo butyrate.
We used the oxazolidinone derived from the corresponding (S) phenylalanine as optically active 
scaffold.12 The alcohol obtained through a reduction with borane in THF was subsequently cyclised 
with dimethylcarbonate in basic conditions.13
The lithium salt of  43, obtained by reaction of BuLi with oxazolidinone, was made reacted with 
hydrocinnamoyl chloride affording  44. NaHMDS was used for the Claisen reaction between the 
optically  active  intermediate  and  t-Bu bromoacetate  14,  15,  then  45 was  hydrolized  with TFA in 
CH2Cl2 and the carboxylic acid 46 was attempted to reduce with borane in THF. 16
Unfortunately this last step afforded the alcool 47 only in low yield, so the first approach resulted in 
a fail due to the low overall yield (Scheme 3.16).
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Scheme 3.16. Theoretical synthetic plan for the obtainment of (R)-34a 
A different synthetic protocol was adopted.
Acting through this pathway (scheme 3.17), was possible to achieve, in a reasonable overall yield, 
the optically active methyl γ-iodo-α-benzyl butyrate. 
γ-benzyloxy butyric  acid  49 was synthesized  refluxing butyrolactone  48 in toluene with benzyl 
bromide and powdered potassium hydroxide.  The carboxylic  group of resulting acid was made 
reactive through the formation of a mixed anhydride with ethyl chloroformate (50).
Lithium salt of 43, previously prepared from 43 and BuLi, was cannulated in the ethereal solution 
of 50 in order to obtain 51. 17
Claisen reaction between 51 and benzyl bromide in presence of NaHMDS afforded diastereoisomer 
52. Chiral oxazolidone was cleaved with lithium hydroxide and hydrogen peroxide17 and benzylic 
protection was removed through hydrogenolysis to afford the optically active lactone (R)-34a.
Lactone ring opening was made with trimethylsilyl iodide and the iodo carboxylic acid (R)-54 was 
esterified  almost  immediately  with  trimethylsilyl  diazomethane  and  purified  through  flash 
chromatography (scheme 3.17).18
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Scheme 3.17. Synthetic pathway for (R)-55.
Manufacture  of  optically  active  ester  (R)-31a followed  the  same  synthetic  pathway  as  for  the 
racemic one, but the use of boiling acidic mixture led to a drop in optical activity of the resulting 
acid (Scheme 3.18). 11
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Scheme 3.18. Acidic cleavage of ester led to racemisation.
A mild hydrolysis for the removal of the methyl ester was object of an intense research, so we’ve 
looking for a protecting group more easily removable.
In the following scheme, tried protecting groups are depicted.
Br COOH
Ph
O
Ph
O
1 ) (Me )3 SiI
2 ) 4 -Me OBn OH
a  o r b
a ) Ac Ot-Bu , HClO4
b ) MOMCl, NEt3 ,  DCM
X
X
Scheme 3.19. Attempts for protection using 36a and 35a.
Methoxymethylene  chloride was used for esterification of small  amount  of racemic acid in dry 
dichloromethane  with poor  results.  A contemporary ring  opening of  lactone  with trimethylsilyl 
iodide in DCM and esterification with 4-methoxybenzylic alcool was attempted  18, resulting in an 
unstable ester which underwent to lactonization. Same problem occurred with the introduction of a 
t-Bu using AcOt-Bu and perchloric acid. 19
Despite the attempts, no one of the protections used afforded a stable ester.
Basic hydrolysis wasn’t tolerated by thiazolidinedionic ring which undergo to decomposition, then 
a cleavage with NaCN in try methanol was tried with no results.
S
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Scheme 3.20. No convertion with mild basic hydrolysis.
Modification on arylalkylidenic portion.
Further modifications was made on the thiazolidinedionic lead 29 following computational chemists 
advice in order to increase the potency of inhibition and the selectivity over MMPs.
The  cinnamylidenic  chain  of  the  lead  compound  29,  was  substituted  with  a  benzylidenic  one 
carrying, in para position, a substituted phenoxy moyety.
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Scheme 3.21. Synthesis of compound 58.
The designed synthesis was developed in order to obtain a library of compounds even if the activity 
of compound 58  led us to abandoned this scaffold.
After some attempts, we started from N-alkylated thiazolidinedione with butyric chain.
Then Knovenagel condensation between 4-hydroxybenzaldehyde and alkylated thiazolidinedione 
led prevalently to the E form of compound 56. 20
Compound 56 was the starting material for the developmental of a library due to the phenolic group 
easily etherifiable using the appropriate boronic acid through an Ullmann-like reaction.21
Basic hydrolysis was avoided due to side-reactions and consequent distruction of molecule. For this 
reason, acidic conditions are a “must” for  thiazolidinedionic derivatives.
A comparation in the activity between lead and compound 58 is report in table 3.7.
Table 3.7 Comparation of the inhibitory activity of lead compound 29 versus 58.
IC50 (µM)
Compd MMP-1 MMP-2 MMP-3 MMP-9 MMP-13 MMP-14
29
N
S
O
O
OH
O
93±8 2.7±0.2 110±26 - 22±0.6 21±2
58
N
S
O
O
OH
O
O
18±1.7 20±2.6
Synthesis of thiohydantoinic derivatives.
Regarding optimization of lead 30 (depicted in Table 3.5), an N-alkylation on the thiohydantoinic 
ring with a benzylic substituent was theorized as a good choice for raise inhibitory activity from 
computational chemists, then a synthetic plan was developed (scheme 3.21)
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Scheme 3.22 Synthetic pathway for the manufacture of inhibitors 62 and 63.
59 was  obtained  through  condensation  between  salicylaldehyde  and  thiohydantoine  in  acqueos 
ethanol, in presence of triethylamine. Alkylation of the phenolic hydroxyl with ethyl bromoacetate 
gave compound 60. 22, 23 N-alkylation with substituted benzyl halide afforded compounds 61 or 62. 
Hydrolysis has been carried out with lithium hydroxide using a mixture of methanol and water as 
solvent. Acidification with 1N hydrochloric acid, afforded the free carboxylic acid. 
However, the negative IC50 values, (table 3.8), led us to discard this kind of molecules.
Table 3.8 IC50 of compounds 62 and 63.
Molecule
IC50
MMP-13
(M)
HN
H
N
O
S
O
OH
O
30
67
HN
N
O
S
O
O
OH
O
63
97±9.5
HN
N
O
S
O
OH
O
62
27±3.5
Pyridopyrimidinone derivatives.
Synthesis and activity.
Sartini et all. in 2007 developed a pyridopyrimidone scaffold based aldose reductase inhibitor with 
good activity. 24 
N
N
OH O
R1
R
Scheme 3.23. General formula of Sartini’s anti-oxidants.
The particolar structure of pyridopyrimidinone similar to that of some pirone-based inhibitors led us 
to explore the chelating properties of pyridopyrimidinone scaffold as zinc chelating agent. 
A longer phenyl chain was adviced for a better interaction with the lipophilic pocket S1’ of target 
MMPs. 25
A synthesis for elongation of aromatic chain was elaborated (scheme 3.23). Claisen reaction 
between 4’-iodoacetophenone and dimethyl carbonate afforded the corresponding methyl 
oxopropanoate 64. Heating 64 with 2-amino-6-hydroxy pyridine and poliphosphoric acid afforded 
pyridopyrimidinone 65 which was purified through flash chromatography. 
A Suzuki reaction took place between 65 and substituted phenyl boronic acid. The product was 
recrystallized from a large amount of boiling AcOEt.
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Scheme 3.24. Synthetic pathway for the manufacture of pyridopyrimidinone 67.
Resulting products was very hard to purified. Only the biphenyl derivative was obtained (R=H).
It was tested on MMP-13 and the resulting value of 42±3.6 M led us to discontinue the synthesis 
of this kind of compounds.
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CHAPTER 4
                             Experimental Section
General
Commercially available  chemicals  were purchased from SigmaeAldrich or Alfa Aesar and used 
without  further  puriﬁcation,  NMR  spectra  were  obtained  with  a  Varian  Gemini  200  MHz 
spectrometer. Chemical shifts (d) are reported in parts per million downﬁeld from tetramethylsilane 
and referenced from solvent references.  Melting points were measured with a Kofler apparatus. 
Chromatographic  separations  were  performed  on  silica  gel  columns  by  ﬂash  (Kieselgel  40, 
0.040e0.063  mm;  Merck)  or  gravity  column  (Kieselgel  60,  0.063e0.200  mm;  Merck) 
chromatography.  Reactions  were  followed  by  thin-layer  chromatography  (TLC)  on  Merck 
aluminium silica gel (60 F254) sheets that were visualized under a UV lamp.
Evaporation was performed in vacuo (rotating evaporator). 
Scheme 3.8, 3.9
General procedure for the N alkylation of either saccharines and phtalimides.
50 mmol of either saccharines or phtalimides were dissolved in 150 ml of absolute ethanol. An 
equimolar amount of fresh sodium metallic was allowed to react in 150 ml of absolute ethanol and 
once dissolved,  resulting sodium ethoxide  solution was added to  the saccharine  or phthalimide 
solution.
A  precipitate  formed,  and  after  stirred  for  one  hour,  the  solvent  was  removed  under  reduced 
pressure. The remaining solid consist in the sodium salt of the corresponding heterocycle was pure 
enough for successive steps.
Phthalimidic  or  saccarinic  sodium salt  (10 mmol)  was  dissolved  in  5  ml  of  dry DMF, and an 
equimolar amount of  bromoalkanoic ester was added. The reaction mixture was stirred and heat to 
reflux and allowed to react.
After completion (generally at least 3 hours), the mixture was cooled to room temperature and all 
the  volatile  materials  were  removed  under  vacuum.  The  residue  was  dissolved  in  CH2Cl2 and 
washed with water. The CH2Cl2 was evaporated under vacuum, and the residue was purified  by 
recrystallization.
The pure ester was hydrolyzed with the aim of NaOH (1.5 eq, 1.5 mmol, 59 mg) in 20 ml of a 2:1 
MeOH/ Water mixture. The solvent was removed under vacuo and the residue was dissolved in 
water.  Acidification  of the solution with HCl 1N afforded a precipitate  which was filtered  and 
crystallized from methanol.
13a. N-acetylsaccharin.
1H NMR 12.48 (DMSO-d6) (s, 1H, -COOH), 8.32 – 8.28 (d, 1H, ArH, J = 
8), 8.14- 8.00 (m, 3H, ArH), 4.01 (s, 1H, -CH2COOH).
Melting Point 212-215°C
13b. N-propionylsaccharin.
1HNMR (DMSO-d6) 12.41 (s, 1H, -COOH), 8.33 – 8.29 (d, 1H, ArH, J = 
8), 8.14- 8.00 (m, 3H, ArH), 3.99 – 3.92 (t, 2H, Jmin = 6 Jmax = 14, 
-CH2CH2COOH), 2.77 – 2.70 (t, 2H, -CH2COOH).
Melting Point 164-165°C
13c. N-butirrylsaccharin.
1HNMR (DMSO-d6) 12.41 (s, 1H, -COOH), 8.33 – 8.29 (d, 1H, ArH, J 
= 8), 8.14- 8.00 (m, 3H, ArH), 3.99 – 3.92 (t, 2H, Jmin = 6 Jmax = 14, 
-CH2CH2COOH),  2.77  –  2.70  (t,  2H,  -CH2COOH),  1.92  –  1.99  (q, 
-CH2CH2CH2COOH).
Melting Point 117-118°C 
23a. N-butirrylphtalimide-5-benzamide.
1HNMR (DMSO-d6) 12.48 (s, 1H, -COOH), 10.44 (s, 1H, -NH-), 
8.20 (s, 1H, ArH), 8.00 – 7.53 (m, 7H, ArH), 3.55 -3.48 (t, 2H, 
Jmin = 6, Jmax = 14, -CH2CH2COOH), 2.34 – 2.27 (t, 2H, Jmin =8, J 
max =14, -CH2COOH), 1.83–1.77 (q, 2H, -CH2CH2CH2COOH).
23b. N-butirrylphtalimide-5-phenylacetylamide.
1HNMR  (DMSO-d6)  12.48  (s,  1H,  -COOH),  10.44  (s,  1H, 
-NH-), 8.20 (s, 1H, ArH), 8.01 – 7.53 (m, 7H, ArH), 3.67 (s, 
1H,  -COCH2Ph),  3.56  -3.49  (t,  2H,  Jmin =  6,  Jmax =  14, 
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-CH2CH2COOH),  2.36  –  2.29  (t,  2H,  Jmin =8,  J  max =14,  -CH2COOH),  1.83–1.77  (q,  2H, 
-CH2CH2CH2COOH).
18b.  N-Boc-5-nitrophtalimide.To a magnetical stirred suspention of 
4-nitroftalimide (1,92 g, 10,0 mmol) in 5 ml of anhydrous acetonitrile 
in a three necked round bottomed flask, flame-dried and purged with 
nitrogen,  is  added  di-t-butylbicarbonate  (2.29  g,  10.5  mmol)  and  a 
catalitycal amount of DMAP (2 mol%, 24 mg).
A carbon dioxide evolution occur.
After 4 h, the reaction is end. The solvent is evaporated under r.p. and the residue is crystallized 
dissolving it in the minimum amount of AcOEt and crashing the solubility with P.E. 60-80°C.
The obtained crystals are filtered on a Buchner funnel, washed with fresh P.E. and dried.1
Yield 96%
1HNMR (CDCl3) 8.77 (s, 1H, ArH), 8.71 – 8.67 (d, 1H, J= 8 Hz, ArH), 8.19 – 8.15 (d, 1H, J= 8 Hz, 
ArH), 1.66 (s, 9H, -C(CH3)3).
19a. 4-aminoisoindoline-1,3-dione.
Same procedure used for 26.
1 HNMR (DMSO-d6) 10.68 (s, 1H, NH), 8.49 – 8.45 (d, 1H, ArH), 7.77 – 7.69 (t, 
1H, ArH ), 7.48 – 7.45 (d, 1H, ArH),  6,34 (s, 2H, -NH2). 
19b. 5-aminoisoindoline-1,3-dione.
Same procedure used for 26.
1HNMR (DMSO-d6) 10.71 (s, 1H, NH), 7.44- 7.40 (d, 1H, J= 8) 6.84 – 6.75 (t, 
2H), 6,39 (s, 2H, -NH2). 
26. N-Boc-5-aminophtalimide. A flame-dried 500 ml round bottomed 
flask is charged with 4-nitroftalimide (x g), 150 ml absolute ethanol 
and Pd/C (5mol%).
After consumption of starting material (TLC, overnight), the mixture is 
filtered on celite and the filtrate concentrated at r.p.
The yellow flakes product were pure enough for successive steps.
Yield Quantitative
1HNMR (CDCl3) 7,57-6,86 (m, 3H, ArH), 6,68 (s, 2H, -NH2), 1,51 (s, 9H, -C(CH3)3)
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Melting Point 290-295°C
General procedure for the amide formation.
A solution of 100 mg (0.010 mol) of 19a, 19b or 26 in 1.9 mL of anhydrous pyridine ( 5 ml/ mmol) 
was cooled to 0  °C  under  nitrogen, and 1.1 eq. of the corresponding acyl chloride was added with 
stirring.
After  24  h  at  room temperature  under  nitrogen,  the  mixture  was  concentrated,  and  1  mL  of 
absolute methanol was  added. The resulting mixture was poured into 10 ml of a stirred solution of 
5:5 ml of water/glacial acetic acid. Separated solid was recrystallized from 95% ethanol and then 
recrystallized from absolute methanol to give the title compounds. 2
27a. N-Boc-5-(phenylbenzamido)phtalimide.
1 HNMR (CDCl3)  10.78  (s,  1H,  -NH),  8.31  (s,  1H,  C-H), 
8.13 – 8.09 (d, 1H, J= 8, C-H), 7.97 – 7.93 (d, 2H, J= 8, C-
H ), 7.84 – 7.78 (dd, 1H, Jmin = 2.9, Jmax = 8.2), 7.58 (m, 3H, 
ArH).  13CNMR (CDCl3)170.03, 168.12, 164.11, 135.72, 135.02, 132.61, 132.21, 128.44, 126.49, 
124.24, 117.91, 117.39, 80.92, 27.83.
Yield 89%
Melting Point >300°C
27b. N-Boc-5-(4-chlorobenzamido)phtalimide.
Yield 76%
1H  NMR  (CDCl3)  8.27-7.50  (m,  8H)  1.60  (s,  9H, 
-C(CH3)3)  13CNMR  (CDCl3)  164.42,  163.25,  155.22, 
144.06, 136.29, 132.04, 129.39, 129.26, 127.84, 123.76, 123.33, 122.18, 113.47, 81.54, 27.98.
Melting Point > 300°C
27c. N-Boc-5-(4-phenylbenzamido)phtalimide.
Yield 63%
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1HNMR (CDCl3) 8.28-7.43 (m, 13H C-H), 1.64 (s, 9H –CCH3) 13CNMR (CDCl3) 170.05, 168.15, 
164.12, 135.75, 135.00, 132.61, 132.21, 129.51 128.44, 128.01, 126.49, 124.20, 117.81, 117.34, 
80.88, 27.83.
Melting Point >300°C
20a. 3-phenylbenzamidophtalimide.
1HNMR (DMSO-d6) 11.50 (s, 1H, NH), 10.37 (s, 1H, ammidic NH), 8.72 – 8.68 
(d, 1H, ArH), 7.77 – 7.69 (t, 1H, ), 7.51 – 7.48 (d, 1H, J = 6 ), 7.42 – 7.34 (m, 5H, 
ArH).  13CNMR  (DMSO-d6)  170.14,  168.03,  164.17,  135.82,  135.22,  132.68, 
131.99, 128.44, 126.49, 124.24, 117.99, 117.39.
Melting Point 285 – 289 °C
20b. 4-phenacetylphtalimide.
1HNMR (DMSO-d6) 11.37 (s, 1H, NH), 9.73 (s, 1H, ammidic NH), 8.49 – 8.45 
(d, 1H, ArH), 7.77 – 7.69 (t, 1H, ), 7.48 – 7.45 (d, 1H, ), 7.38 – 7.30 (m, 5H, 
ArH), 3.83 (s, 2H, PhCH2CO-). 13CNMR (DMSO-d6) 169.52, 169.32, 167.95, 
135.60, 135.01, 133.94, 132.08, 128.86, 127.97, 126.37, 124.05, 117.08, 43.03.
Melting Point >290°
Scheme 3.10
General procedure for the formation of N-hydroxyphtalimide derivatives.
0,50 mmol of a  N-Boc derivative (27a-c)  was dissolved in 1 ml  of CH3CN in a  10 ml round 
bottomed flask, then 0,1 ml of an acqueous solution (50% w/w) of Hydroxylamine is added.
After 4.5 h, the reaction is quenched with 5 ml of diethyl ether, and the precipitate (white to pink) is 
filtered on a Buchner funnel and washed twice with small portion of fresh Et2O (10 ml x 2).
 Mild and convenient one pot synthesis of N-Hydroxyimides from N-unsubstituted imides. 1
28a. N-Hydroxy-4-benzamidophtalimide.
N
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O
N
H
OH
O
NH
O
ONHO
NH
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Yield 76%
1HNMR (DMSO-d6) 10.78 (s, 1H, -OH), 8.31 (s, 1H, C-H), 8.13 – 8.09 (d, 1H, J= 8, C-H), 7.97 – 
7.93 (d, 2H, J= 8, C-H), 7.84 – 7.78 (dd, 1H, Jmin = 2.9, Jmax = 8.2), 7.58 (m, 3H). 13CNMR (DMSO-
d6) 170.14, 168.03, 164.17, 135.82, 135.22, 132.68, 131.99, 128.44, 126.49, 124.24, 117.91, 117.39.
Melting Point 212 – 213°C
28b. N-Hydroxy-4-(4-chlorobenzamido)phtalimide.
Yield 18%
1H NMR (DMSO-d6) 11.13 (s, 1H, -OH), 10.85 (s, 1H, -NH-), 
8.36 (s, 1H, C-H), 8.21-8.18 (d, 2H, J= 6), 8.08 – 8.05 (d, 1H, J= 
6), 7.80-7.76 (d, 1H, J = 8), 7.60 – 7.56 (d, 2H, J= 8) 13CNMR (DMSO-d6) 164.42, 163.25, 144.06, 
136.29, 132.04, 129.39, 129.26, 127.84, 123.76, 123.33, 122.18, 113.47.
Melting Point > 290°C dec.
28c. N-Hydroxy-4-(4-phenylbenzamido)phtalimide.
Yield 33%
1H NMR (DMSO-d6) 10.84 (s, 1H, -OH), 10.63 (s, 1H, -NH-), 
8.28-7.46 (m, 12H, ArH).
13CNMR  (DMSO-d6)  170.11,  168.22,  164.35,  135.75,  135.01,  132.67,  132.19,  129.49  128.38, 
128.00, 126.33, 124.19, 117.81, 117.37.
Melting Point > 300°C dec.
General Method for N-Boc deprotection.
N-Boc aryl phtalimide was placed in a flame dried round bottomed flask, protected from moisture 
with a drying tube and dissolved in dry dichloromethane, then trifluoroacetic acid was added and 
the reaction was allowed to stir at room temperature.
After 1 hour TLC shown completion of reaction. Al volatile substances was removed and residue 
was crystallized with methanol.
20c. 4-benzamidophtalimide.
Yield 90%
1 HNMR (DMSO-d6) 11.50 (s, 1H, NH) 10.78 (s, 1H, amidic -NH), 
8.31 (s, 1H, C-H), 8.13 – 8.09 (d, 1H, J= 8, C-H), 7.97 – 7.93 (d, 
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2H, J= 8, C-H), 7.84 – 7.78 (dd, 1H, Jmin = 2.9, Jmax = 8.2), 7.58 (m, 3H).  13CNMR (DMSO-d6) 
170.14, 168.03, 164.17, 135.82, 135.22, 132.68, 131.99, 128.44, 126.49, 124.24, 117.91, 117.39.
Melting Point >290°C
20e. 4-(4-chlorobenzamido)phtalimide.
Yield 93%
1H NMR (DMSO-d6)  11.13  (s,  1H,  -NH),  10.85  (s,  1H,  amidic 
-NH-), 8.36 (s, 1H, C-H), 8.21-8.18 (d, 2H, J= 6), 8.08 – 8.05 (d, 
1H, J= 6), 7.80-7.76 (d, 1H, J = 8), 7.60 – 7.56 (d, 2H, J= 8)
13CNMR  (DMSO-d6)  164.42,  163.25,  144.06,  136.29,  132.04,  129.39,  129.26,  127.84,  123.76, 
123.33, 122.18, 113.47.
Melting Point > 290°C
20f. (4-phenylbenzamido)phtalimide.
Yield 89%
1H NMR  (DMSO-d6)  10.84  (s,  1H,  -NH),  10.63  (s,  1H,  amidic 
-NH-),  8.28-7.46  (m,  12H,  ArH). 13CNMR  (DMSO-d6)  169.87, 
168.01, 164.35, 135.75, 135.01, 132.67, 132.19, 129.49 128.38, 128.00, 126.33, 124.19, 117.81, 
117.37.
Melting Point > 290°C
Scheme 3.12, 3.13, 3.14, 3.15
33. γ-butyrolactone triphenylphosphonium bromide
A mixture of 2 g of -bromo butyrolactone and 6 grams of triphenylphosphine was 
mechanically stirred and refluxed in 20 ml of THF for six hours. A white to grey 
powder formed copiously. 
Heating was removed and the mixture was allowed to reach room temperature.
About 100 ml of diethyl  ether was added, the precipitate was filtered on a Buchner funnel and 
washed several times with fresh ether.
Quantitative Yield. 
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Spectroscopic data correspond to that reviewed in literature. 3
The triphenylphosphine bromide salt obtained was dissolved in DCM and a stechiometrical amount 
of t-BuOK was added. After 30 minutes, the inorganic solid constituted of potassium bromide was 
filtered and the solvent was removed at reduced pressure from the filtrate.
The white-to-grey solid can was used in the successive step without further purification. 4
34a α -benzylidenebutyrolactone. 
In a 50 ml round bottomed flask with magnetic agitation, the phosphor ylide and the 
benzaldehyde are mixed together without solvent.
In few second a very strong exotermic reaction take place, with the complete melting of the solid 
compound and the formation of a very viscous amber liquid. The reaction mustn’t be cooled. 
The liquid which was mainly constituted of triphenylphosphine oxide and the olefinic compound 
will turn in solid on cooling.
Flash chromatography (P.E./AcOEt 5:5) afforded the title compound as a crystalline solid.
If a purer stuff was desired, diethyl ether can be use as washing solvent in order to remove all of 
coloured impurities. 5
Yield 91%
Spectroscopic data correspond to that reviewed in literature. 6
35a. α -benzylbutyrolactone. 
In a flame-dried 250 ml round bottomed flask, compound X was added in 100 ml of 
absolute ethanol.
Palladium on carbon was added (5mol%).
The reaction was stirred under an hydrogen atmosphere for two hours, until all the starting material 
reacts (TLC). 
The green solution was then filtered on a pad of celite and the alcohol in the filtrate was removed at 
reduced pressure. A slightly yellow oil was obtain.
Yield almost quantitative. 5, 6
1HNMR (CDCl3) 7.38 – 7.20 (m, 5H, ArH), 4.26 – 4.13 (m, 2H, -CH2CH2OOC-), 3.31 – 3.23 (m, 
1H,), 2.90 – 2.70 (m, 2H,), 2.35 – 2.21 (m, 1H), 2.11 – 1.95 (m, 1H).  13CNMR (CDCl3) 177.84, 
138.24, 128.19, 127.73, 125.69, 65.68, 39.64, 34.72, 27.02.
36a. α -benzyl--bromobutyric acid. 
Ph
O
Br
OH
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In a 100 ml round bottomed flask, 1g Of 35a and 20 ml of AcOH/HBr 33% are stirred and heated at 
80°C for one hour.
(The formation of the acid was easily detected using PhMe/AcOEt/AcOH 6,5:3:0.5 as eluant for 
TLC).
Reaction was left to cool and 20 ml of water are added.
Petroleum ether was used as solvent for the extraction (50 ml x 3) to avoid formation of emulsions.
The organic layer was washed with brine (20 ml x 2), 20% sodium thiosulphate solution (20 ml x 2) 
and again with brine (10 ml x 2), dried over magnesium sulphate, filtered and concentrated under 
reduced pressure. 5
Yield 79% as a brown oil
NMR (CDCl3) 7.35 – 7.28 (m, 5H, Ph), 3.46 – 3.35 (q, 2H, Jmin = 8, Jmax = 22, -CH2CH2Br), 2.67 – 
2.59 (t, 2H, Jmin = 8, Jmax = 16, PhCH2CH2-, ), 2.39 – 2.11 (m, 1H, =CH-), 2.05 – 1.77 (m, 2H, 
-COOCH2CH2-).
37a. Methyl α-benzyl-γ-bromobutyrrate. 
In a 50 ml round bottomed flask the compound from the previous reaction was 
dissolved in 10 ml of anhydrous THF. 
A large excess of thiolyl chloride was added together to few drops of DMF.
The reaction was stirred for 15 minutes, then THF and unreacted thionyl chloride were removed 
with the aid of reduced pressure.
A large excess of absolute ethanol was added to the acyl chloride (25 ml) and the mixture was left 
on stirring for ten minutes.
After stripping of ethanol a brown oil pure enough for successive step was obtained. If a purer ester 
was desired a flash chromatography (P.E./AcOEt 7:3) can be carried out. 5
Yield = 75% as a white oil.
1HNMR (CDCl3) 7.35 – 7.28 (m, 5H, Ph), 3.65 (s, 3H, -COOCH3), 3.46 – 3.35 (q, 2H, Jmin = 8, Jmax 
= 22, -CH2CH2Br), 2.67 – 2.59 (t, 2H, Jmin = 8, Jmax = 16, PhCH2CH2-, ), 2.39 – 2.11 (m, 1H, =CH-), 
2.05 – 1.77 (m, 2H, -COOCH2CH2-).
34b.α-phenethylydenbutyrolactone. 
Same procedure used for the manufacture of -benzylydenbutyrolactone.Ph
OO
Ph
O
Br
O
1HNMR (CDCl3) 7.47 – 7.43 (d, 1H, J = 8 PhCH2CH-), 7.36-7.22 (m, 5H, Ph), 4.39-4.32 (t, 2H, 
JMIN= 8, Jmax = 16 Hz -COOCH2CH2-), 3.56 – 3.52 (d, 2H, J = 8, PhCH2CH=), 2.52 – 2.44 (m, 
1H, -COOCH2CH2-), 2.29 – 2.10 (m, 1H, -COOCH2CH2-).
Yield 68% as a white oil. 5
35b. α -phenetylbutyrolactone.
Same procedure used for the manufacture of -benzylbutyrolactone
1HNMR (CDCl3) 7.36 – 7.22 (m, 5H, Ph), 4.42 – 4.33 (t, 1H, Jmin = 9, Jmax = 18, -COOCH2CH2-), 
4.26 – 4.18 (t,  1H, Jmin = 8, Jmax = 14, -COOCH2CH2-),  2.80 – 2.73 (t,  2H, Jmin = 6, Jmax = 14, 
PhCH2CH=), 2.56 – 2.26 (m, 3H), 2.03 – 1.74 (m, 2H).
Yield = 98% as a white oil. 5
36b. 4-bromo-2-phenethylbutanoic acid.
1HNMR (CDCl3) 7.35 – 7.17 (m, 5H, Ph), 3.73 (s, 3H), 3.46 – 3.35 (q, 2H, Jmin = 
8, Jmax = 22), 2.67 – 2.59 (t, 2H, Jmin = 8, Jmax = 16, PhCH2CH2-, ), 2.39 – 2.11 (m, 
1H, =CH-), 2.05 – 1.77 (m, 4H, -COOCH2CH2-).
Yield = 90% as a brownish oil. 5
37b. Methyl 4-bromo-2-phenetylbutanoate.
1HNMR (CDCl3) 7.35 – 7.17 (m, 5H, Ph), 3.73 (s, 3H), 3.74 (s, 3H, -COOCH3) 
3.46 – 3.35 (q, 2H, Jmin = 8, Jmax = 22), 2.67 – 2.59 (t,  2H, Jmin = 8, Jmax = 16, 
PhCH2CH2-, ), 2.39 – 2.11 (m, 1H, =CH-), 2.05 – 1.77 (m, 4H, -COOCH2CH2-).
Yield = 77% as a white oil. 5
38.  (5Z)-5-((E)-3-phenylallylidene)thiazolidine-2,4-dione.  In  a  250  ml 
round  bottomed  flask  x  g  of  thiazolidinedione  and  x  g  of  trans 
cinnamaldehyde  are  stirred  in  x  ml  of  ethanol.  Piperidine  was  added  as 
catalyst and the blend was stirred under reflux  for 24 hours. 
Ethanol was stripped and the concentrated solution was dropped in cold water, acidified with glacial 
acetic acid and the resulting yellow solid filtrate on a Buchner funnel.
A small sample for analytical purpose can be made using toluene as crystallizing solvent. 8
Yield 64%
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1HNMR (DMSO-d6  ) 12.42 (s, 1H, NH), 7.70-7.66 (d, 1H, PhCHCHCH-), 7.53-7.39 (m, 5H, Ph) 
7.34-7.27 (d, 1H, PhCHCHCH), 7.26 (s, 1H, PhCHCHCH-), 7.00-6.87 (dd, 1H, PhCHCHCH-).
39a.  methyl  2-benzyl-4-((5Z)-2,4-dioxo-5-((E)-3-
phenylallylidene)thiazolidin-3-yl)butanoate.
In  a  flame-dried  50  ml  three  necked  round  bottomed  flask 
equipped for magnetic stirring and purged with nitrogen,  was 
charged  with  475.6  mg  (2.05  mmol)  of  38 in  5  ml  of  anhydrous  DMF.  When  the  solid  was 
dissolved, NaH (60% mineral oil dispersion, 82 mg, 2.05 mmol) was added.
A visible evolution of hydrogen take place, and a clear yellow solution was obtained.
Then 372 mg of 36a (1.37 mmol) was added dropwise, and the mixture stirred overnight at r.t.
After consumption of ester (tlc), DMF was removed, and a yellow solid was obtained.
Flash chromatography (P.E./AcOEt 7:3) afforded title compound as a yellowish solid.
Yield 64%
1HNMR (CDCl3) 7.61-7.55 (d, 1H, J = 12, PhCHCHCH-), 7.51-7.14 (m, 10H 2xPh), 7.10-7.03 (d, 
1H, J= 14 Hz, PhCHCHCH-), 6.79-6.66 (dd, 1H, Jmin = 12, Jmax = 15 PhCHCHCH-), 3.81 – 3.74 
(t, 2H, Jmin = 8, Jmax = 14 Hz), 3.64 (s, 3H) 3.04-2.71 (m, 3H ), 2.16 – 1.98 (m, 1H) 1.94 – 1.80 
(m, 1H). 13CNMR (CDCl3) 175.40, 175.16, 165.68, 143.90, 141.31, 138.00, 135.61, 133.50, 130.15, 
129.17, 128.92, 128.59, 127.82, 127.15, 126.20, 123.01, 120.69, 52.04, 42.52, 42.28, 40.13, 29.95.
Melting Point 50-52°C
31a.  2-benzyl-4-((5Z)-2,4-dioxo-5-((E)-3-
phenylallylidene)thiazolidin-3-yl)butanoic acid.
In a 25 ml round bottomed flask 270 mg (0.65 mmol) of 39a was 
dissolved in 6 ml of AcOH, then 1.5 ml of concentrated HCl 36% was added to the clear solution. 
Reaction was heat to 120°C for four hours and the acid mixture was removed at reduced pressure. 
The  yellow  residue  was  purified  throught  flash  chromatography  (gradient  eluition  CH2Cl2 10 
CH2Cl2/MeOH 9.5:0.5)
Yield 71%
1HNMR (CDCl3) 7.61-7.55 (d, 1H, J = 12, PhCHCHCH-), 7.51-7.14 (m, 10H 2xPh), 7.11-7.04 (d, 
1H, J= 14 Hz, PhCHCHCH-), 6.93 - 6.80 (dd, 1H, Jmin = 12, Jmax = 15 PhCHCHCH-), 3.84 – 
3.77 (t, 2H, Jmin = 8, Jmax = 14 Hz), 3.04-2.71 (m, 3H ), 2.12 – 1.99 (m, 1H) 1.93 – 1.80 (m, 1H). 
13CNMR (CDCl3) 174.47, 174.34, 164.53, 138.60, 137.85, 136.69, 129.22, 129.17, 129.11, 128.90, 
128.60, 127.84, 127.53, 126.73, 45.14, 40.24, 38.53, 29.99.
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Melting Point 109-112°C
39b.  Methyl4-((5Z)-2,4-dioxo-5-((E)-3-
phenylallylidene)thiazolidin-3-yl)-2-phenethylbutanoate.
Same procedure used for 39a.
1HNMR (CDCl3) 7.61-7.55 (d, 1H, J = 12, PhCHCHCH-), 7.51-
7.14 (m, 10H 2xPh), 7.10-7.03 (d, 1H, J= 14 Hz, PhCHCHCH-), 6.79-6.66 (dd, 1H, Jmin = 12, 
Jmax = 15 PhCHCHCH-), 3.81 – 3.74 (t, 2H, Jmin = 8, Jmax = 14 Hz), 3.64 (s, 3H) 3.04-2.71 (m, 
3H), 2.22 –1.75 (m, 3H). 13CNMR (CDCl3) 175.40, 175.16, 165.68, 143.90, 141.31, 138.00, 135.61, 
133.50,  130.15,  129.17,  128.92,  128.59,  127.82,  127.15,  126.20,  123.01,  120.69,  52.04,  42.52, 
42.28, 40.13, 34.01, 29.95.
31b. 4-((5Z)-2,4-dioxo-5-((E)-3-phenylallylidene)thiazolidin-3-
yl)-2-phenethylbutanoic acid.
Same procedure used for 31a.
1HNMR (CDCl3) 7.61-7.55 (d, 1H, J = 12, PhCHCHCH-), 7.51-
7.14 (m, 10H 2xPh), 7.10-7.03 (d, 1H, J= 14 Hz, PhCHCHCH-), 6.79-6.66 (dd, 1H, Jmin = 12, Jmax = 
15 PhCHCHCH-), 3.81 – 3.74 (t, 2H, Jmin = 8, Jmax = 14 Hz), 3.04-2.71 (m, 3H ), 2.22 –1.75 (m, 
3H).  13CNMR (CDCl3) 175.47, 175.14, 165.60, 143.50, 141.29, 138.10, 135.61, 133.50, 130.15, 
129.17, 128.92, 128.86, 127.82, 127.15, 126.20, 123.01, 120.69, 42.52, 42.28, 40.73, 34.01, 29.95.
Melting Point 203-204° C
41.  methyl  2-benzyl-4-(2,4-dioxo-5-(3-
phenylpropyl)thiazolidin-3-yl)butanoate.
39a  (100mg,  0.24  mmol)  was  dissolved  in  absolute  ethanol. 
Pd/C was added (5 mol%) and the mixture was left stirring at rt 
overnight. Reaction mixture was filtered through celite and concentrated.  41 was pure enough for 
next step. 1HNMR (CDCl3) 7.51-7.14 (m, 10H 2xPh), 3.77 (t, 1H), 3.64 (s, 3H), 3.04-2.71 (m, 3H ), 
2.55 (t, 2H), 2.12 – 1.99 (m, 3H) 1.93 – 1.80 (m, 2H), 1.55 (m, 2H).
Yield = 70% as a sticky liquid.
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42.  2-benzyl-4-(2,4-dioxo-5-(3-phenylpropyl)thiazolidin-3-
yl)butanoic acid
Hydrolysis procedure is the same for 39a o 39b.
1HNMR (CDCl3) 7.51-7.14 (m, 10H 2xPh), 3.77 (t, 1H), 3.04-
2.71 (m, 3H ), 2.55 (t, 2H), 2.12 – 1.99 (m, 3H) 1.93 – 1.80 (m, 2H), 1.55 (m, 2H).
Yield = 42% as a sticky liquid.
Scheme 3.16.
 
 43. (S)-2-amino-3-phenylpropan-1-ol.
 A 500 ml three-neck round-bottom flask was fitted with a magnetic stirbar, was 
fitted with a reflux condenser, and an addition funnel.  The flask was charged with 6.92 g (183 
mmol) sodium borohydride and 200 mL of  THF (predried over sodium). L-phenylalanine (12,54 g, 
76 mmol) was added in one portion.  The remaining neck was sealed with a septum and an argon 
line attached, and the flask was cooled to 0 "C in an ice bath.  A solution of 19.30 g (76 mmol of 
iodine dissolved in 50 mL of THF  was poured into the addition funnel and added slowly and 
dropwise over 30 min resulting in vigorous evolution of hydrogen. After addition of the iodine was 
complete and gas evolution had ceased, the flask was heated to reflux for 18 h  and  then cooled  to 
room  temperature,  and methanol was added cautiously until the mixture became clear. After 
stirring 30 min, the solvent was removed by rotary evaporation  leaving  a  white  paste  which  was 
dissolved by addition of  150 mL of  20% aqueous KOH. The solution was stirred for 4 h and 
extracted with 3 X 150 mL of methylene chloride. The organic extracts were dried  over sodium 
sulfate  and  concentrated in  vacuo, affording a crude product.
Cristallization from toluene yield 6.8 g of amino alcohol.
Yield 59%
Spectroscopic datas correspond to that reviewed in literature. 9
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43a. (S)-4-benzyloxazolidinone
A dry, 50 ml, three-necked flask was equipped with a magnetic stirrer and a 
distillation head. The flask was charged with 3.1 g (20.7 mmol) of (S)-
phenylalanol, 0.3 g (2.02 mmol) of anhydrous potassium carbonate, and 3.4 mL (40.33 mmol) of 
dimethyl carbonate. The mixture was lowered into an oil bath, preheated to 100°C, and was stirred 
until dissolution was achieved (ca. 5 min). The theoretical amount of methanol was collected from 
the reaction over a 2.5-hr period. The oil bath was removed on cessation of the methanol 
distillation. After the light-yellow solution was cooled to ambient temperature, it was diluted with 
30 mL of dichloromethane, transferred to a separatory funnel, and washed with 10 mL of water. 
The organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated on the 
rotary evaporator affording 200 g a white crystalline solid. This material was taken up into 30 mL 
of a hot 2:1 ethyl acetate–hexane solution, filtered while hot, then allowed to crystallize to afford 
large white plates. 10
Obtained: 2.2 g
Yield 60%
44. (S)-3-(3-phenylpropanoyl)-4-benzyloxazolidin-2-one.
To  43a (704 mg,  4.0 mmol)  in THF (8 mL),  was added n-BuLi (2.5 M in 
hexane, 2.5 mL, 4.0 mmol) dropwise at -78°C.   After complete addition, the 
solution  was stirred  for  5  min  at  -78 °C.  A solution  of  Hydroxycinnamoyl 
chloride in 5 mL of THF was then added dropwise at -78 °C over 10 minutes 
and the mixture was stirred at -78 °C for 1 h.  The reaction was quenched with 1 mL of saturated 
NH4Cl solution and extracted with ethyl acetate (3 x 20 mL).  The extracts were combined, washed 
with brine (2 x 5 mL), dried over MgSO4, and concentrated to afford a yellow oil. Crystallization 
(from ethyl acetate/P.E.) provided a colorless solid.
Obtained 915 mg as a solid.
Yield 74%. 
Spectroscopic data and melting point are referred. 11
45.  (R)-tert-butyl3-benzyl-4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-4-
oxobutanoate.
To a solution of 1,20 g of 44 ( 3.9 mmol) in dry THF (10 ml/ mmol) at -78 °C 
was added 7.15 ml of sodium hexamethyldisilazide (4.29 mmol, 1.1 equiv, 1.0 
NO
O O
Ph
CO2t-Bu
NO
O O
Ph
N
H
O
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O
M in THF) via syringe. The solution was then stirred at -78 °C for 1.5-2 h. To the reaction was 
added 0.86 ml of tert-butyl bromoacetate (5.85 mmol, 1.5 eq.) via syringe. Alkylation was allowed 
to proceed at -78 °C until TLC analysis indicated complete consumption of the starting material (3-
6 h). The reaction flask was allowed to warm to 0 °C before the contents were partitioned between 
saturated aqueous NH4Cl (10 ml) and 50 mL of EtOAc. The layers were separated, and the aqueous 
layer was extracted with three 20 mL portions of EtOAc. The combined organic extracts were dried 
(MgSO4),  filtered  through  cotton,  and  concentrated  in  vacuo  to  yield  a  solid  which  was 
recristallized from a minimal volume of hexane/ether to afford white crystals or purified through 
flash chromatography (P.E. / AcOEt 9:1).
Spectroscopic data match to that reviewed in literature. 12
Yield = 74% 
46. (R)-3-benzyl-4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoic acid.
To  a  0  °C  solution  of  the  ester  (0.312  mmol)  X  ml  of  a  70:30  (v/v) 
CH2Cl2/trifluoroacetic  acid solution was added. The solution was stirred at 
room temperature for 3.5 h, and the contents were concentrated in vacuo and 
under  high  vacuum  to  yield  a  residue.  The  residue  was  dissolved  in  the 
minimum amount  of ethyl  ether and precipitate with Petroleum ether 60-80. A white solid was 
obtained. 12
Yield 89%
1H NMR (CDCl3) 7.39-7.18 (m, 10 H), 4.59-4.44 (m, 2H), 4.13-4.08 (dd, J = 8.9, 1H), 3.99-3.91 
(m, 1H), 3.37-3.29 (dd, J = 13.3, 1H), 3.01 (dd, J = 13.1), 2.85 (dd, J = 16.9, 1H), 2.76 (dd, J = 13.5, 
1H), 2.45 – 2.34 (dd, J =13.1,1H).
47. (R)-3-benzyl-4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanol.
430 mg of  46 (1.16 mmol) was dissolved in 9 ml of dry THF. BH3.THF was 
added dropwise (1.16 ml, 1.16 mmol) at 0°C. The mixture was stirred for six 
hours, then quenched with MeOH. The solvents was removed in vacuo and the 
residue was purified through  flash chromatography. (P.E./AcOEt 7:3)
1H NMR (CDCl3) 7.37-7.20 (m, 10 H), 4.99 (s,1H, -OH), 4.59-4.44 (m, 2H), 4.05- 3.99 (dd, J = 
8.9, 1H), 3.76 -3.70 (t, 2H, Jmin = 6, Jmax = 12 Hz), 3.37-3.29 (dd, J = 13.3, 1H), 3.01 (dd, J = 
13.1), 2.85 (dd, J = 16.9, 1H), 2.76 (dd, J = 13.5, 1H), 2.45 – 2.34 (dd, J =13.1,1H).
Yield = 9% as a viscous oil. 13
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Scheme 3.17
49. -(benzyloxy)butanoic acid.
To  a  solution  of 83 mL  (0.70  mol)  of benzyl  bromide  and  15.0  g (0.174  mol)  of g-
butyrolactone in  300  mL  of toluene  was added  49.2  g (0.745  mol)  of freshly  crushed  85% 
KOH.  The  mixture  was  stirred  at reflux,  under  N,,  for three  days,  then  partitioned  between 
300  mL  of H20  and  150 mL  of  diethyl  ether.  The  layers  were  separated,  and  the  aqueous 
layer  was extracted  with  additional  ether  (2  x  150  mL).  The  ether/toluene  layers  were  set 
aside,  and  the  aqueous  layer  was  cooled  with  an  ice  bath,  then  acidified  with  150 mL  of  3 
M  H2S04  solution.  The  acidic  suspension  was  then  extracted  with  CH2Cl2, (3  x  150  mL). 
The  combined  CH2Cl2  layers  were  dried  and  concentrated  to  8.85  g (26.2%)  of  a  colorless 
oil. 
The  ether/toluene  layer  was  concentrated  to  remove  most  of the  diethyl ether,  and  the 
residue  was  heated  at  reflux  with  80  mL  of H20  and  16  g  of NaOH for  20  h.  The  layers 
were  separated,  then  the  aqueous  layer  was  diluted  to  200  mL. This  was  extracted  with 
ether  (3  x  50  mL).  The  aqueous  layer  was  treated  with  a slurry  of  20  mL  H2SO4,  in  100 
mL  of ice.  The  acidic  suspension  was  then  extracted with  CH,Cl,  (3  x  100  mL).  The 
combined  CH2Cl2  layers  were  dried  and concentrated  to  22.44  g (66%)  of additional  product 
for  a total  yield  of  31.29  g (92%). This  acid  was  used  without  purification  in  the  next  step. 
14, 15
51. (S)-3-(4-(benzyloxy)butanoyl)-4-benzyloxazolidin-2-one.
In a three-necked flask equipped with a mechanical stirrer, 49 (1.1 g, 5.65 
mmol) was dissolved in dry Et2O (9.5 mL/ mmol). Triethylamine (0.8 mL, 
5.65 mmol) was added, and the mixture was stirred at rt for 15 min. This 
solution was cooled to 0 °C, and ethyl chloroformate (0.54 mL, 5.65 mmol) 
was added. A thick white precipitate  immediately formed.  This solution was warmed to rt  and 
stirred for an additional 1 h. In a separate flask, (4S)-benzyl oxazolidinone  43a (1 g, 5.65 mmol) 
was dissolved in THF (1.5 ml/ mmol) and cooled to -78 °C.
 n-butyllithium (1.6 M in hexanes, 3.53 mL, 5.65 mmol) was added dropwise to this solution. The 
43a solution was transferred via cannula into the solution containing the anhydride, the mixture was 
stirred for 30 min at -78 °C, and then was warmed to 0 °C for an additional 30 min. The solution 
was quenched with satd. aq. NH4Cl and extracted with Et2O. The combined organic extracts were 
Bn O COOH
ONBn O
OO
washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. Purification by column 
chromatography (9:1 hexanes/EtOAc) afforded 15.2 g (46.3 mmol, 88 %) of the product as a pale 
yellow oil. 16
Report: [ ]23D + 44.8 (c 1.0, CHCl3), 16 found: [ ]23D + 40.2 (c 1.0, CHCl3).
52.  (S)-3-((R)-2-benzyl-4-(benzyloxy)butanoyl)-4-benzyloxazolidin-2-
one.
In a three-necked flask equipped with an internal thermometer, NaHMDS 
(1 M in THF, 3.1 mL, 3.05 mmol) was cooled to -78°C, and a solution of 
51 (900 mg,  2.54  mmol)  in  2.5  mL of  THF (1  ml/  mmol)  was  added 
dropwise via syringe at a rate such that the internal temperature was maintained below -70 °C. This 
mixture was stirred for 30 min, after which benzyl bromide (638  mg, 1.5 eq., 3.80 mmol) in THF 
(1 ml/ mmol) was added dropwise. The reaction mixture was allowed warm to -50 °C and stirred 
for an additional 24 h at this temperature. The solution was then quenched with satd. aq. NH4Cl and 
was  extracted  with  Et2O.  The  combined  organic  extracts  were  washed  with  brine,  dried  over 
MgSO4, filtered, and concentrated in vacuo. The crude product was purified by
column chromatography (8:2 P.E./EtOAc) to afford 640 mg of the alkylated product as a clear oil. 16
Yield: 57%
53. (R)-2-benzyl-4-(benzyloxy)butanoic acid.
To a solution of 620 mg of 52 (1.4 mmol) dissolved in 4.5 ml of a mixture 3:1 
THF/water poured to 0°C, was added hydrogen peroxide (6 eq., 8.4 mmol 0.85 
ml  30% acqueous  solution)  and 118 mg of  LiOH idrate  (2  eq.  2.8  mmol). 
Hydrolysis proceeded for 1 h. Acidification of the aqueous layer, extraction, 
and concentration yielded the carboxylic acid as a clear oil, pure enough for next step.
1HNMR (CDCl3) 11.27 (s, 1H, -COOH), 7.36- 7.18 (m, 10H, ArH), 4.47 (s, 2H, PhCH2O-), 3.55 – 
3.49 (t, 2H, Jmin = 6, Jmax = 12 Hz, -OCH2CH2- ), 3.09 – 2.74 (m, 3H, -CH-, CH2Ph), 2.07 – 1.57 
(m, 2H, -OCH2CH2-).
(R) – 34a. (R)-2-benzylbutyrolactone.
In a dried 50 ml round bottomed flask, was dissolved 53 (350 mg, 1.23 mmol) in 25 
ml of absolute ethanol,  Pd/C was added to the mixture (5 mol%).  The flask was 
purged with hydrogen and the mixture was left stirred for one hour.
ONBn O
OO
Bn O
O
OH
O
Ph
O
The mixture was filtered trough a short pad of celite and on concentration yielded (R) – 34a as a 
white oil.
[] D 20 (c 1.0, MeOH) + 52.2
Yield = 97%
1HNMR (CDCl3) 7.38 – 7.20 (m, 5H, ArH), 4.26 – 4.13 (m, 2H, -CH2CH2OOC-), 3.31 – 3.23 (m, 
1H, CH), 2.90 – 2.70 (m, 2H, PhCH2- ), 2.35 – 2.21 (m, 1H, -CH2CH2OOC- ), 2.11 – 1.95 (m, 1H, 
-CH2CH2OOC- ).  13CNMR (CDCl3) 177.84, 138.24, 128.19, 127.73, 125.69, 65.68, 39.64, 34.72, 
27.02.
 
(R) – 55. (R)-methyl 2-benzyl-4-iodobutanoate.
(R)  –  34a (88  mg,  0.5  mmol)  was  dissolved  in  dry  CH2Cl2 (1ml/mmol). 
Trimethylsilyl  iodide (1 eq.,  0.5 mmol,  0.07 ml)  was added, and mixture was 
allowed to react avoiding light.
After 2 hours lactone was hydrolyzed. Reaction was quenched with 20 ml of moist CH2Cl2.
Sudden organic phase was then washed with sodium thiosulphate 5% strength (5 ml x 2), dried over 
MgSO4, and concentrated afford 137 mg (90% of yield).
This residue was dissolved in 3 ml of a mixture of PhMe / MeOH 2:1, treated with 0.3 ml of 
trimethylsilyl diazomethane (2.0 M in Hexanes) and left stirred at r.t. for half hour.
Concentration afforded an oily residue which was purified through flash chromatography (P.E./ 
AcOEt 8:2). Obtained 138 mg. 17
Yield = 98% as a white oil.
[] D20 (c 1.0, MeOH) + 11.5
1HNMR  (CDCl3)  7.32  –  7.15  (m,  5H,  ArH),  3.66  (s,  3H,  -COOCH3),  3.24  –  3.18  (m,  2H, 
ICH2CH2-), 2.97 – 2.78 (m, 3H, ), 2.37 – 1.95 (m, 2H). 
Scheme 3.18
(R)-31a.  (R)-methyl  2-benzyl-3-((5Z)-2,4-dioxo-5-((E)-3-
phenylallylidene)thiazolidin-3-yl)propanoate
Same procedure used for 31a.
[α] D20 (c 1.0, MeOH) – 17.44.
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Scheme 3.21
  Ethyl 4-thiazolidinedionebutanoate
A 50  ml  flame-dried  round  bottomed  flask  was  charged  with  20  ml  of 
absolute ethanol and metallic Sodium (0.23g 10 mmol).
Meanwhile in another flame-dried round bottomed flask, thiazolidinedione ( 1.17g, 10 mmol) was 
dissolved in 30 ml of absolute ethanol. The ethanolic solution of sodium ethoxide was added to the 
thiazolidinedione solution and colour turned from yellow to grey-white. 
After removal of ethanol at r.p. to residue, consisting in the sodic salt of thiazolidinedione, was 
dissolved in 5 ml of dry DMF, and ethyl 4-chloro butyrate (2,0 g, 12 mmol) was added.
The reaction was leave on reflux for 2 h. The solvent was partially removed, ice was added and 
once melt the acqueous phase was extract with ethyl acetate (20 ml x 3).
The organic phase was dried over MgSO4, filtered, and the solvent removed at r.p.
A yellow oil was obtained.
Purification through flash chromatography (P.E./AcOEt 6:4).afford a white to gray crystalline solid. 
An analytical sample was stored at +4°C. 18
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56.  Ethyl  4-((Z)-5-(4-hydroxybenzylidene)-2,4-
dioxothiazolidin-3-yl)butanoate.          
Ethyl  4-thiazolidinedionebutanoate  (300  mg,  1.30  mmol),  4-
hydroxybenzaldehyde  (158  mg,  1.30  mmol)  and  piperidine 
(1.30 mmol, 123 mg) were dissolved in 10 ml of Ethanol 7.5 
ml/mmol compound). The mixture was stirred at room temperature for 18 h.
After removal of the solvent an orange oil was obtained. The compound was crystallized dissolving 
it in Glacial acetic acid and adding water to the obtained solution affording white needles.
Yield 37%
Melting Point 115-120°C
1HNMR (DMSO-d6) 10.20 (s, 1H, -OH) 7.80 (s, 1H, CH-), 7.49- 7.45 (d, 2H, J= 8, ArH), 6.92 – 
6.88 (d, 2H, J= 8, ArH), 4.05 – 4.00 (q, 2H, OCH2CH3), 3.69 – 3.62 (t, 2H, NCH2CH2CH2COOEt 
Jmin = 8, Jmax = 14 Hz, ), 2.36 – 2.29 (t, 2H, NCH2CH2CH2COOEt Jmin = 8, Jmax = 14), 1.85 – 1.77 
(q, 2H, NCH2CH2CH2COOEt).
Melting Point 115-120°C.
57.  Ethyl  4-((Z)-5-(4-phenoxybenzylidene)-2,4-
dioxothiazolidin-3-yl)butanoate.
In a flame dried round bottomed flask equipped with a 
calcium chloride tube, was sequentially charged with 56 
(150 mg, 0.45 mmol), phenylboronic acid (90 mg, 0.44 mmol), cupric acetate (90 mg, 0.44 mmol) 
and 10 ml of dry CH2Cl2.
the mixture was allowed to become homogeneous, then powdered activated Molecular sieves 4 A 
(0.3 g) and triethylamine (5 eq, 2.25 mmol, 228 mg) was added.
The reaction was stirred overnight, then filtered. The residue was washed with DCM (10 ml x 4), 
and the filtrate was concentrated at r.p.
The residue was purified through flash chromatography (P.E. /AcOEt 8:2) affording a white oil that 
solified on standing in a crystalline solid. 19
Yield = 61% as a white solid.
Melting Point = 55-60°C
1HNMR (DMSO-d6) 7.90 (s, 1H, CH), 7.69 – 7.64 (d, 2H, J= 10, ArH), 7.48 – 7.43 ( Jmin = 7, Jmax = 
10 Hz, ArH), 7.29 – 7.21 (t, 1H, Jmin = 7, Jmax = 16 Hz, ArH), 7.14 – 7.10 (m, 4H, ArH), 4.12 (t, 2H, 
-COOCH2CH3), 3.72 – 3.65 (t, 2H, Jmin = 6 Jmax = 13 Hz NCH2CH2CH2COOEt), 2.31 – 2.22 (t, 2H, 
Jmin= 9 Jmax= 18 NCH2CH2CH2COOEt),  1.85 – 1.79 (q, 2H, NCH2CH2CH2COOEt),  1.30 (t,  3H, 
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COOCH2CH3).  13CNMR 173.05, 166.77, 165.13, 158.58, 154,51, 131.81, 131.47, 129.69, 127.11, 
123.94, 119.16, 117.64, 61.18, 30.26, 21.92, 14.17, 12.16.
58. 4-((Z)-5-(4-phenoxybenzylidene)-2,4-
dioxothiazolidin-3-yl)butanoic acid
58 (100 mg, 0.26 mmol) was dissolved in glacial AcOH 
(4 ml/mmol) and HCl 37% acid (1 ml/mmol).
The mixture was then heated to 100°C obtaining after 4 h the carboxylic acid. The acid precipitate 
upon cooling was filtered on a Buchner funnel and recovered as mother-of-pearl flakes.
Yield = 34% as a white solid
Melting Point 138-142°C
1HNMR (DMSO-d6) 7.90 (s, 1H, CH), 7.69 – 7.64 (d, 2H, J= 10, ArH), 7.48 – 7.43 ( Jmin = 7, Jmax = 
10 Hz, ArH), 7.29 – 7.21 (t, 1H, Jmin = 7, Jmax = 16 Hz, ArH), 7.14 – 7.10 (m, 4H, ArH), 3.72 – 3.65 
(t,  2H,  Jmin =  6  Jmax =  13  Hz  NCH2CH2CH2COOEt),  2.31  –  2.22  (t,  2H,  Jmin=  9  Jmax=  18 
NCH2CH2CH2COOEt), 1.85 – 1.79 (q, 2H, NCH2CH2CH2COOEt).  13CNMR (DMSO-d6) 173.05, 
166.77, 165.13, 158.28, 154,46, 131.72, 131.45, 129.66, 127.06, 123.98, 119.17, 117.66, 30.26, 
21.92, 12.16.
Scheme 3.22
59.  Ethyl  2-(2-formylphenoxy)acetate. In  a  250  ml  round  bottomed  flask, 
salicilaldehyde (7,0 g, 4.65 ml, 42 mmol), ethyl bromoacetate (5.80 g 42 mmol), 
K2CO3 (42 mmol, 5,80 g) in anhydrous acetone (75 ml) were refluxed for 2 
hours under an inert atmosphere. The suspension was filtered, and the filtrate was concentrated at 
r.p. The crude product was purified through flash chromatography (P.E./AcOEt 8:2).
Yield 88% as white needles. 20
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59a.  (E)-5-(2-(Ethyl  O-acetoxy)benzylidene)-thiohydantoin. 
Triethylamine  (3.34  ml,  24  mmol)  was  added  to  a  mixture  of 
thiohydantoin (1.39 g, 12 mmol) and 2.50 g (12 mmol) of 59 in 15 ml of 
absolute ethanol under a nitrogen atmosphere.
The reaction was left  under magnetical  stirring for 24 hours,  then the 
solvent was stripped at r.p. and the resulted residue was triturated with Et2O, filtered on a Buchner 
funnel and washed with small portion of fresh ether until the colour turn from intense orange to a 
yellow powder.
Yield 73%
Melting Point 240°C
1HNMR (DMSO-d6) 9.94 (s, 1H, Ar-CH-Het ), 7.76-7.01 (m, 4H), 6.79 (s, 1H), 4.93 (s, 2H), 4.15 
(q, 2H, -CH2CH3 ), 3.38 (s, 1H), 1.22 (t, 3H, CH3CH2-).
General Procedure for N alkylation 
A three necked, flame-dried 50 ml round bottomed flask purged with nitrogen was charged with 
59 and NaH (1 mmol, 40 mg 60% mineral oil dispersion). 
After 30 minutes the evolution of hydrogen ceased and the sodium salt of 59 formed.
Then the appropriate benzyl bromide (2.5 eq, 2.5 mmol) dissolved in dry DMF (1 ml/mmol) was 
added drop wise over three hours at room temperature.
After the addition of the appropriate benzyl bromide, the reaction was refluxed overnight.
DMF was removed in vacuo and the residue purified through flash chromatography.
60.    Ethyl (E)-5-(2-(O-acetoxy)benzylidene)-3-(4- 
methylbenzyl) thiohydantoin.
Flash chromatography eluent: PhMe/AcOEt 7:3
Yield 11%
MELTING POINT 148-153°C
1HNMR (DMSO-d6) 8.91 (s, 1H, NH), 7.39 (s, 1H, CH) 7.35- 7.09 (m, 7H, ArH), 6.76 (s,1H, CH), 
6.81 – 6.77 (d, 1H, J= 8 Hz ArH), 4.74 (s, 2H, -CH2COOEt), 4.56 (s, 2H, -CH2C4H6CH3), 4.31 (q, 
2H, -COOCH2CH3), 2.35 (s, 3H, -C6H4CH3), 1.32 (t, 3H, -COOCH2CH3)
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61.  Ethyl  (E)-5-(2-(O-acetoxy)benzylidene)-3-(4-
methoxybenzyl thiohydantoin.
Flash chromatography eluent: PhMe/AcOEt 9:1
Yield 83%
Melting Point 135-140°C
1HNMR (DMSO-d6) 8.91 (s, 1H, NH), 7.38 (s, 1H, CH) 7.35- 7.08 (m, 7H, ArH), 6.76 (s,1H, CH), 
6.81 – 6.77 (d, 1H, J= 8 Hz ArH), 4.74 (s, 2H, -CH2COOEt), 4.56 (s, 2H, -CH2C4H6 CH3), 4.31 (q, 
2H, -COOCH2CH3), 3.71 (s, 3H, -C6H4OCH3), 1.32 (t, 3H, -COOCH2CH3).
General procedure for hydrolysis of ethyl ester
In a round bottomed flask, 0.15 mmol of the corresponding ester was dissolved in 4 ml of a mixture 
3:1 MeOH/H2O.
The solution obtained was then poured at 0°C under magnetical stirring and LiOH.H2O (6 eq, 0.90 
mmol ) was added in one only portion.
The reaction was allowed to reach r.t.  and stirred for 30 minutes, time after which the solution 
becomes clear. After conversion, the solvent was evaporated to r.p. and the residue was dissolved in 
1 ml of water. The solution was cool to 0°C with an ice bath. Few drop of HCl 3% strength were 
added until a milky precipitate appear. The solid was filtered on a sintered funnel and dried. The 
product obtained was very pure and no crystallization was required.
62.  (E)-5-(2-(O-acetoxy)benzylidene)-3-(4-methylbenzyl) 
thiohydantoin
Yield 69%
Melting Point 150-155°C
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1HNMR (DMSO-d6) 8.91 (s, 1H, NH), 7.39 (s, 1H, CH) 7.35- 7.09 (m, 7H, ArH), 6.76 (s,1H, CH), 
6.81 – 6.77 (d, 1H, J= 8 Hz ArH), 4.74 (s, 2H, -CH2COOEt), 4.56 (s, 2H, -CH2C4H6CH3), 2.35 (s, 
3H, -C6H4CH3).
63.  (E)-5-(2-(O-acetoxy)benzylidene)-3-(4-
methoxybenzyl) thiohydantoin
Yield 73%
Melting Point 124-128°C
1HNMR (DMSO-d6)  8.91  (s,  1H,  NH),  7.38  (s,  1H,  CH) 
7.35-  7.08  (m,  7H,  ArH),  6.76  (s,1H,  CH),  6.81  –  6.77  (d,  1H,  J=  8  Hz  ArH),  4.74  (s,  2H, 
-CH2COOEt), 4.56 (s, 2H, -CH2C4H6 CH3), 3.71 (s, 3H, -C6H4OCH3).
Scheme 3.24
64. Methyl 3-(4-iodophenyl)-3-oxopropanoate.
4-  iodoacetophenone  (10.00  mmol,  2.45  g)  was  dissolved  in  30 ml  of 
dimethyl carbonate. NaH ( 440 mg 1.1 eq, 11 mmol 60% mineral oil) was 
slowly added and the mixture was refluxed for 2 hours.
Then solvent was removed in vacuo and residue crystallized from boiling P.E. 21
Yield 86%
1HNMR 7.81 (d, 2H), 7.68 (d, 2H), 3.59 (s, 3H, -CH3), 3.48 (s, 2H, CH2).
65. 6-hydroxy-2-(4-iodophenyl)-4H-pyrido[1,2-a]pyrimidin-4-one.
A mixture of 2-aminopyridine (110 mg, 1.00 mmol) and 64 ( 456 mg, 1.50 
mmol) in PPA (2.00 g) was heated at 100 °C for 1 h while stirring with a 
glass stick. The thick syrup thus obtained was slowly poured into crushed 
ice, and the resulting suspension was neutralized with 5% aqueous sodium hydroxide. The solid 
precipitate  was  collected  by  filtration,  washed  with  water,  and  purified  through  flash 
chromatography (P.E./ AcOEt 8:2). 22 1HNMR 11.40 (s, 1H, -OH), 7.96-7.58 (m, 5H, ArH), 7.10 (d, 
2H, ArH), 6.09 (s, 1H).
67a. 6-hydroxy-2-(4-biphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one.
O
HN N
O
S
H
HOOC OCH3
O O
OCH3
I
N
N
OH O
I
N
N
OH O
Ph
To 2 ml of toluene in a test tube with screw cap in inert atmosphere  was added Pd(AcO)2 ( 11.3 mg 
0.05 mmol, ), PPh3  (52 mg, 0.2 mmol). The mixture was stirred for 15 minutes until the formation 
of complex occurred. Then add 64 (304 mg, 1.0 mmol), Phenylboronic acid (134 mg, 1.1 eq, 1.1 
mmol) and 2 ml of Na2CO3 2N.
The mixture was stirred for six hours, then reaction was dump in 30 ml of AcOEt and washed with 
brine (5 ml x 3). The organic layer was dried on MgSO4, filtered, and concentrated in vacuo.
The residue was purified through flash chromatography (P.E./ AcOEt 5:5) and the product obtained 
further crystallized from AcOEt. 23
Yield= 7% as a yellow amorphous powder.
Melting Point 159- 163°C
1HNMR 11.40 (s, 1H, -OH), 7.96-7.47 (m, 10H, ArH), 7.10 (d, 2H, ArH), 6.11 (s, 1H).
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CHAPTER 5
                          The ubiquitin–protein ligase system
The Ubiquitin-proteasome system.
The ubiquitin–protein ligase system (or ubiquitin protease system; UPS) was discovered in the early 
1980. The presence of three enzymes was described and named as E1, E2 and E3. 1 Ubiquitin is a 
small protein made by 76 aminoacids
Regulation of protein degradation is an essential aspect of cell signalling. 
Cells must be able to respond immediately to environmental changes to maintain homeostasis or to 
undergo specified developmental decisions; Ubiquitin–proteasome system (UPS) is responsible for 
much of the regulated proteolysis in the cell. 2
The ubiquitin and ubiquitin-like pathways are integral to the normal function of eukaryotic cells. 
Protein  turnover,  trafficking,  and  the  modulation  of  protein  function  have  been  ascribed  to 
ubiquitination.
Ubiquitination of target proteins proceeds in a stepwise format involving E1, E2 and E3 enzymes. 
The  ubiquitin  system  is  hierarchically  structured  and  confers  specificity  for  protein  substrates 
through a multitude of E3 ubiquitin ligases. A few E1 ubiquitin-activating enzymes exist; however, 
at least 50 E2 ubiquitin-conjugating enzymes and about 500 E3 ubiquitin ligases are codified by 
human genome.
Ubiquitination occurs in three steps.
In the first: 
- ubiquitin or ubiquitin-like proteins (Ubl) are activated through an ATP-dependent manner by the 
enzymes E1 which catalyzes the adenylation of the Ubl C-terminus. E1 enzyme forms a thioester 
between a conserved catalytic cysteine and the Ubl. Next, E1 is loaded with a second Ubl molecule, 
followed by its C-terminal adenylation.
In the second:
- The E1-Ubl thioester complex recruits a conjugating enzyme denoted as E2 to facilitate transfer of 
the thioester-linked Ubl to a conserved E2 cysteine (transthioesteriﬁcation). 
And in the last:
- E2 enzyme interacts with a specific E3 ubiquitin-protein ligase resulting in the autoubiquitination 
of E3 or ubiquitination of target proteins on specific lysine residues. A schematic representation is 
depicted in Figure 4.1. 
Target proteins can be ubiquitinated in a manner that their function, localization, or stability within 
the cell results altered. Generally, the addition of one to four ubiquitin molecules to a target protein 
leads  to  a  change  in  its  localization  and/or  function.  The  addition  of  many ubiquitin  moieties 
(polyubiquitination)  leads to protein degradation by the 26S proteasome,  a 2.5-MDa molecular 
machine built from approximately 31 different subunits, which catalyzes protein degradation. 3
Figure 4.1. Schematic function of Ubiquitin- Proteasome system. 1 
The 20S and 26S Proteasome Complexes
Proteasomes consist of a large proteinase complex with multiple catalytic domains that are located 
in  the  cytosol  as  well  as  the  eukaryotic  cell  nucleus.  The  S26 proteasome is  a  multi-catalytic 
protease complex consisting of a S20 core, and S19 regulatory particle, or cap. 
The 20S catalytic subunit contains six unique ATPdependent serine protease sites, divided equally 
between  chymotrypsin,  trypsin  and  caspase-like  activities.  The  biological  importance  of  the 
proteasome is defined by the observation that deletion of 13 out of 14 genes which make up the core 
S20 complex result in lethal phenotypes. 4
The E1 enzymes
The Ub-E1 consists of four building blocks: 
- the  adenylation  domains  (hereafter,  IAD  and  AAD,  for  ‘‘inactive’’  and  ‘‘active’’ 
adenylation domain, respectively), the latter of which binds ATP and Ub; 
- the catalytic  cysteine half-domains,  which contain the E1 active site cysteine  (hereafter, 
FCCH and SCCH, for ‘‘ﬁrst’’ and ‘‘second’’ catalytic cysteine half-domain, respectively) 
inserted into each of the adenylation domains;
- a four-helix bundle that represents a second insertion in the IAD and immediately follows 
the FCCH; 
- the C-terminal ubiquitin-fold domain (UFD), which recruits speciﬁc E2s. 5
Catalytic mechanisms of canonical E1s
The catalytic mechanism is best characterized for the ubiquitin E1, UBA1. After UBL C-terminal 
adenylation, the ubiquitin~AMP is attacked by the catalytic Cys of UBA1, producing a covalent 
thioester  linkage  between  the  Cys  sulfhydryl  of  UBA1  and  the  C-terminus  of  ubiquitin. 
Subsequently,  UBA1  catalyzes  the  adenylation  of  a  second  ubiquitin  molecule.  Thus,  UBA1 
becomes asymmetrically loaded with two ubiquitin molecules at distinct active sites: ubiquitin (T 
stand for thioester) is covalently linked to the E1’s Cys via a thioester bond; ubiquitin (A, stand for 
adenylation)  is  associated  non-covalently  at  the  adenylation  active  site.  Ultimately,  UBA1 
physically associates with a cognate E2 conjugating enzyme, and a thioester transfer reaction ensues 
whereby the C terminus of ubiquitin (T) is transferred to the E2’s catalytic Cys. Individual steps of 
the E1 reaction are reversible. Progression of the cascade is driven by release of the small molecule 
products PPi and AMP in the first and second steps, respectively.
A curious feature of the E1-E2 cycle is the asymmetric double-loading of E1 with two ubiquitin
molecules. Why double load? Although a previous study showed that a partially purified UBA1-
ubiquitin complex containing only the single ubiquitin (T) is capable of transferring the ubiquitin to 
an E2, this transfer is accelerated by ubiquitin (A) adenylate. Also, UBA1 adenylation active site 
mutants  generate  an  E2-Ub complex  more  efficiently  than  would  be  predicted  based  on  their 
crippled adenylation of ubiquitin, further indicating cross-talk between the adenylation active site 
and E1-E2 thioester transfer. Coupling the second adenylation reaction with ubiquitin transfer to E2 
might make the cascade energetically or conformationally favourable, or might prevent the E1 from 
becoming trapped in an unfavourable conformation. A mechanism similar to the one of UBA1 has 
been  confirmed  for  the  heterodimeric  E1  of  NEDD8,  NAE1-UBA3,  through  biochemical  and 
structural studies. Thus, it is likely that mechanistic and structural studies of a subset of canonical 
E1s provide broad insights into this E1 class as a whole. 6
The E2 enzymes
E2 enzymes are easily recognized from their evolutionarily conserved 150 residue catalytic
`Ubc' domains. Ubcs have a compact structure shaped essentially like a prolate ellipsoid, comprised 
of four -helices, a short 310 helix near the active site, and a four-stranded antiparallel -sheet. On 
the “bottom”, the active site Cys to which Ub (or Ubl) becomes conjugated is nestled in a catalytic 
groove  surrounded  by  highly  conserved  amino  acids  that  mediate  both  thioester  formation 
(reception of Ub from the E1 Ub- activating enzyme) and substrate ubiquitination (isopeptide bond 
formation with a substrate lysine). Most notable is a trio of residues known as the `HPN' motif, 
usually found ten residues to the N-terminal side of the active site Cys. The His is thought to play a 
structural role in forming the E2 active site, whereas the Asn residue is important for mediating the 
catalysis  of  an  isopeptide  between  Ub  and  a  substrate  lysine.  As  the  general  mechanism  for 
ubiquitination suggests, an E2 must interact  with an E1 and an E3; both interactions use partly 
overlapping surfaces on one pole of the Ubc ellipsoid. The E1/E3 interaction site comprised the 
residues on the N-terminal helix, or helix 1 (H1), and loops 4 and 7 (L4 and L7; sometimes referred 
to as L1 and L2). The shared surface implies that an E2 must be free of the E3 before becoming re-
loaded with Ub. Many E2s are characterized by additional segments located within and flanking the 
Ubc domain. For example, Cdc34 has a 12-residue acidic loop near the 310-helix of its Ubc that is 
important for catalyzing poly-Ub chain formation. More common are E2s that contain variable N- 
or C-terminal extensions appended to the Ubc domain. Thus historically, the E2 family has been 
divided into four classes according to the presence of these additional protein segments: Class I, 
Ubc domain only; Class II, Ubc domain plus a terminal extension; Class III, Ubc plus an N-terminal 
extension; Class IV, Ubc plus both N- and C-terminal extensions. However, while the topology of 
the Ubc domain is highly conserved, N- and C-terminal extensions are widely variable in both size 
and structure.  Sizes  of extensions vary from a ~50-residue C-terminal.  Although a tidy way to 
group E2s, the classifications are not predictive for functionality, such as E3s with which a given 
E2 will interact, or whether an E2 transfers mono-Ub or is capable of building a poly-Ub chain. In a 
recent effort to classify E2s, a phylogenetic analysis of similarities within the Ubc domains yielded 
17 different families of E2s. In this scheme, five of the ~45 Human E2s are assigned to the family 
that includes the UbcH5 isoforms while other families have only one or two members. Assigning 
functional significance to each family may have limited utility when there are half as many families 
as  E2s,  and  additional  biochemical  and  functional  characterization  will  be  required  to  lend 
predictive value to this fine-grained classification. 7
Rad6 E2 enzyme.
Rad6 and its human homologues, Rad6a/b, are particularly important E2 enzymes that have been 
shown to be involved in DNA damage tolerance (DDT), histone modification,  and proteasomal 
degradation, a clear intrinsic ability to form ubiquitin chains, although other functions of Rad6 may 
exist. DDT has been extensively characterized as a two-step pathway. In the first step, Rad6/Rad18 
monoubiquitinate PCNA on K164 at stalled replication forks to signal for recruitment of damage-
tolerant  polymerases.  Next,  Ubc13/MMS2/Rad5  can  form  K63-linked  polyubiquitin  chains  on 
modified PCNA to initiate  error-free DNA repair.  In this  process Rad6 monoubiquitinates  only 
PCNA, even in vitro. Rad6a/b, with RNF20/40 (Bre1) as E3 ligase, will monoubiquitinate histone
H2B in human cells on K120 as an essential step prior to H3 methylation by Set1 and Dot1. Finally, 
Rad6 together with Ubr1 is associated with ubiquitin chain formation within the N-rule pathway. In 
this  role,  Rad6 is essential  for the formation of K48 ubiquitin chains on proteins bearing an N 
degron, which marks the target for proteasomal degradation. Interestingly,
Rad18, Bre1,  and Ubr1 all  contain additional  Rad6 recognition sites outside a canonical  RING 
interface. 8
UbcH5b E2 enzyme.
UbcH5b is one of the E2 enzymes that have been demonstrated to form polyubiquitin chains in 
cooperation  with  several  E3  enzymes.  UbcH5b  has  been  postulated  to  gain  access  to  various 
acceptor sites on the substrate in an efficient manner. Its structure has been recently  elucidated. 9
Figure 4.2. Model for catalytic reaction of nucleophilic attack on UbcH5b-Ub. 9
The E3 enzymes
Specificity in targeting proteins for ubiquitination lies mostly in the E3 enzyme. 
There are two major classes of E3 enzymes: 
      -    U- Box.
- The HECT (Homologous  to  the E6-AP Carboxyl Terminus)  -type  E3 ubiquitin  ligases  . 
(These include Smurf1,Smurf2,AIP4,and Nedd4 among others). 
- The RING finger domain proteins.
RING (Really Interesting New Gene) finger protein with ubiquitin E3 ligase activity implicates the 
presence of a double Zn2+ binding motif arranged in a cross-brace structure termed RING-finger, as 
being essential for ubiquitin E3 ligase catalytic activity. 
The critical role of the Zn2+ containing RING domain of BCA2 has been demonstrated by point 
mutation of key zinc-binding cysteine residues leading to the complete loss of enzyme activity.
Figure  4.3. Most  of  the  RING fingers  contain  two  zinc  atoms  (yellow)  coordinated  with  cysteine  or 
cysteine/histidine-rich clusters (red). 2  
 For example, ring finger proteins Mdm2, Efp and BRCA1/BARD have ubiquitin E3 ligase activity 
and have been shown to have a significant biological role in breast and other cancers.
A notable feature of RING E3 ubiquitin ligases is that the enzymatic activity of the E3 ligase can be 
monitored through autoubiquitination of the protein in vitro. 
Autoubiquitination is the process by which the E3 enzymes catalyze the addition of polyubiquitin to 
themselves. This can result in the degradation or change of function of the E3 protein in vivo. 10
The BCA2 E3 ubiquitin ligase.
Many of the known E3 ligases play a role in various diseases, including breast cancer development 
and progression. The Breast Cancer- associate protein 2 (BCA2) is one of this.
BCA2 is an E3 ubiquitin ligase that was isolated from an invasive breast cancer cell line, and has 
been shown to be highly expressed in 56% (530/945) of invasive breast cancers, but not in most 
normal tissues examined. Down-regulation of BCA2 has been shown to inhibit breast cancer cell 
growth and invasiveness. BCA2 is expressed in the cytoplasm and nucleus,  and nuclear BCA2 
correlates with positive estrogen receptor status (p<0.004). The classification of BCA2 as a Really 
Interesting  New  Gene  (RING)-finger  protein  with  ubiquitin  E3  ligase  activity  implicates  the 
presence of a double Zn+2 þ-binding motif arranged in a cross-brace structure, termed RING-finger, 
as being essential for ubiquitin E3 ligase catalytic activity. The critical role of the Zn2+ þ containing 
RING domain of BCA2 has been demonstrated by point mutation of key zinc-binding cysteine 
residues leading to the complete loss of enzyme activity. BCA2 (also known as Rabring7) has been 
found to complex with a cytoplasmic binding partner Rab7, a small GTPase involved in cellular 
endocytosis and trafficking of oncogenic receptor tyrosine kinases (such as epidermal growth factor 
receptor (EGF-R)) for destruction in the lysosome. Hence, targeting BCA2 within breast cancer 
cells may allow Rab7 to fulfill its function in tyrosine kinase receptor degradation, preventing the 
receptor recycling and sustained mitogenic signaling known to contribute to the development of 
resistance to tyrosine kinase inhibitory therapeutics.
Taken together, the data outlined above suggest that BCA2 could prove an important therapeutic 
target within the E3 ubiquitin ligase class for the future treatment of breast cancer.
Given the crucial  role  of  Zn2+ ions in  the catalytic  RING domain  of  BCA2, a  series  of  “zinc-
ejecting”  compounds  from the  National  Cancer  Institute  database  have  been  screened for  their 
ability to inhibit BCA2 activity in BCA2-expressing breast cancer cell lines such as MCF-7. These 
studies have led to the identification of DSF (NSC25953) a registered drug for the treatment of 
alcoholism by virtue of additional ALDH1 activity, as a potent BCA2-inhibitory antitumor agent. In 
this paper, we describe the synthesis and antitumor evaluation of four series of novel “zinc-affinic” 
agents,  in order to optimize selective activity against  recombinant  BCA2 and BCA2-expressing 
breast cancer cell lines. From this antitumor data, we derived SAR insight into BCA2-inhibitory 
pharmacophore requirements, leading to the identification of potent and selective BCA2-inhibitory 
antitumor agents without accompanying ADH-inhibitory activity.
By employing multitumor tissue microarray technology has been found that normal breast, colon, 
and head and neck tumors lack detectable BCA2 expression. Twenty of 20 breast cancers and 15 of 
15 prostate cancers strongly expressed BCA2. Sixty percent of 17 renal cancers had strong BCA2 
staining,  and none of the clear  cell  renal tumors  had detectable  BCA2. Lower levels  of BCA2 
staining were seen in 57% of 16 colon cancers, in 65% of 22 pancreatic tumors, and in 73% of 17 
bladder cancers. Weak expression of BCA2 was seen in 4 of 7 lung tumors and in 6 of 11 head and 
neck tumors.
A second larger tumor tissue microarray study examined BCA2 expression in 945 invasive breast 
cancers. 
Figure 4.4. Expression of BCA2 protein in normal  and tumor tissues.  One hundred twenty-five tumor 
tissues and adjacent normal tissues from the same patient were assembled onto a tissue microarray slide, 
fixed, and probed for BCA2 expression by immunoperoxidase staining (positive reaction, brown). (A) The 
top panel shows representative cores (0.6 mm) of normal breast, colon and head and neck tissues stained for 
BCA2 protein expression. (B) The bottom panel shows strong nuclear and cytoplasmic expression of BCA2 
in breast, prostate, and papillary renal cell cancers, but very weak staining in clear cell renal, colon, and head 
and neck carcinomas.
Comparison with patient data revealed that BCA2 expression correlates with clinical variables such 
as  lymph  node  status,  regional  recurrence,  and  estrogen  receptor  expression  pattern.  Although 
BCA2 expression in the entire cohort did not correlate with overall survival, a subset of patients 
with regional recurrence history revealed that a higher BCA2
is linked with a significant 5-year survival benefit and that a low BCA2 is linked with lymph node 
metastasis.  The  correlation  of  BCA2 expression with  estrogen receptor  positivity  indicates  that 
BCA2 and estrogen receptor  might  be coregulated  and cross-talked at  the transcriptional  level, 
perhaps in the nucleus. 11
Ubiquitination in cancer
Cancer  can  develop  from stabilisation  of  oncoproteins  or,  alternatively,  from destabilisation  of 
tumour suppressor genes. Cancer-associated proteins that have been reported to be regulated by the 
ubiquitin–proteasome  system  include  the  tumour  suppressors,  p53  and  p27,  the  cell  surface 
receptors for growth factors, epidermal growth factor receptor (EGFR) or transforming
growth factor-b Receptor  (TGF-bR) complex,  as well  as cell  cycle  and oncogenic  transcription 
regulators.
A  recent  study  investigated  the  level  of  20S  catalytic  proteasome  core  in  plasma  of  healthy 
individuals  versus  that  of  patients  plasma  having  various  neoplastic  diseases  including  acute 
myeloid  leukaemia  (AML),  Hodgkins  disease,  chronic  myeloproliferative  syndromes  andsolid 
tumours.  The  results  derived  by  comparing  these  individuals  showed  that  the  20S  catalytic 
proteasome core levels in plasma of the pathological states was markedly increased, and was, in 
fact,  up  to  1000-fold  higher  in  patients  with  solid  tumours  compared  with  plasma  of  normal 
subjects.  While  the  number  of  cancer-related  proteins  tagged  with  ubiquitin  and  destined  for 
degradation in the proteasome as well as proteasome particles are manifold, little is known about 
the role of the individual components of the ubiquitin system in tumourigenesis. Only a limited 
number of the ubiquitin-conjugating enzymes and ligases have been examined for their expression 
pattern in a large number of human tumours.
A single E1 enzyme is responsible for the initial ubiquitin activation in mammalian cells. Although 
the  deletion  of  the  gene  has  been  shown to  be  lethal,  an  involvement  in  cancer  has  not  been 
described. An E2 conjugating enzyme (UbcH10) and few E3 ligases studied in relation to cancers, 
were shown to have high expression levels in malignancies. The E2 UbcH10, for which protein 
expression data are lacking, was found at extremely low RNA levels in normal tissues, while RNA 
expression was high in primary tumours such as lung, stomach, uterus and bladder cancers. The 
prototypic  example  of  a  protein  that  plays  a  pivotal  role  in  many cancers  and is  regulated  by 
substrate-specific E3 ubiqutin ligases is p53. The tumour suppressor protein p53 plays a crucial role 
in cell cycle control, DNA repair and apoptosis. Two E3 ligases, namely the RING-type E3 ligase 
Mdm2 and the HECT-type E3 ligase E6-AP can effect its degradation by the proteasome. Cervical 
cancers  have been strongly associated with infections  by the oncogenic human papilloma virus 
(HPV) forms 16 and 18. As a result, the E6 and E7 gene products of HPV are detected in these 
tumours. It is believed that p53 is present at very low levels in cervical cancer cells because it is 
associated with the E6/E6- AP E3 ligase complex, and is therefore rapidly degraded by ubiquitin-
mediated proteolysis.
In the vast majority of tumours, Mdm2 regulates p53 by either inhibiting its transcriptional activity 
or targeting p53 for ubiquitination and proteasomal degradation. 
Thus, overexpression of Mdm2 provides an alternative to p53 mutation and/or deletion leading
to development of cancers. Mdm2 is recognised as the major ubiquitin ligase for p53 and has been 
found overexpressed in several  human tumour types.  While Mdm2 overexpression by means of 
gene amplification is mainly seen in soft tissue sarcomas and gliomas, transcriptional/
translational overexpression has been found in acute lymphoblastic leukaemia (ALL), melanomas
and  breast  carcinomas.  Mdm2 overexpression  was  predictive  for  a  poor  outcome  in  sarcomas, 
gliomas and ALL, but was identified as a favourable prognostic marker in melanoma and breast 
cancer  patients.  Latter  studies indicate  that  Mdm2 might  have tissue-  specific,  p53-independent 
functions in cancers, for example as a regulator of cell proliferation by targeting tumour suppressor 
gene(s) as well as other key proteins governing cell growth (s).
Another  HECT-type  E3 ligase that has emerged as being important  in certain  cancers  is  Smad 
ubiquitination  regulatory  factor-2  (Smurf2).  High-level  expression  of  Smurf2  was  shown  to 
correlate  with  a  poor  prognosis  in  oesophageal  squamous  cell  carcinoma.  Smurf2  directs  the 
ubiquitinylation and proteasomal degradation of R-Smads, and the TGF-b receptor complex. TGF-b 
signalling molecules have been shown to play a crucial role in breast and other cancers and it is 
therefore likely that the Smurf2 HECT-type  E3 ligase will  also have functions in these tumour 
types. A RING-type E3 ligase with proven role in breast cancer is BRCA1. Germline mutations in 
the RING finger of the tumour suppressor gene BRCA1 predispose women to early onset breast 
tumours. BRCA1 ubiquitin ligase activity is enhanced when it is dimerised with BRCA1-associated 
RING  domain  (BARD1)  and  has  been  implicated  in  p53-associated  DNA  damage  response. 
Together,  these  findings  indicate  that  cancer  cells  maintain  a  higher  amount  of  proteolytic 
machinery that would likely enable them to cope with the normal cells proteomic ‘‘repair response’’ 
and either facilitate degradation of tumour suppressor proteins or activation of proto-oncogenes.
From this  generalised  perspective  and  after  considering  the  fact  that  cancer  remains  a  largely 
incurable disease with few long-term treatment options, the ubiquitin–proteasome system evolves 
tantalisingly with a multitude of opportunities for targeted therapeutic Interventions. 1
Many of the known E3 ligases play a role in various diseases, including breast cancer development 
and progression. Among the first RING proteins to be associated with ubiquitination and cancer 
were the multisubunit complex E3 ligases ROC1 and APC11. 11
Expanding understanding of the UPS and its role in human diseases has elicited significant interest 
in the development of small molecules that target specific components of the pathway. The role of 
the UPS in disease is really in its infancy, as only a small fraction (perhaps <20%) of the genes with 
potential links to the pathway based on known sequence motifs have been studied in any detail.
BCA2 and Estrogen Receptor Co-Expression in Invasive Breast Cancer
Estrogen regulates the proliferation and development of tissues expressing estrogen receptors and is 
a risk factor for breast cancer development. Ligand binding activates both estrogen receptor (ER)-
dependent  transcription  and  ER  ubiquitination.  ER  ubiquitination  and  proteasome  activity  are 
intimately linked to ER-dependent transcriptional activation. Proteasome inhibitors and mutations 
that  inhibit  co-activator  binding  both  abrogate  ligand-mediated  ER  proteolysis  and  ERE 
transcriptional  activity.  Different  ligands  stimulate  ER proteolysis  to  different  degrees,  and  the 
ubiquitin  ligases  BRCA1, MDM2, and E6AP can all  stimulate  estrogen-induced transcriptional 
activity. The BCA2 protein is an ubiquitin ligase co-expressed with the ER in breast cancers. We 
have  studied  BCA2 protein  expression  in  a  large  collection  of  over  1,000  invasive  mammary 
carcinomas, termed the Henrietta Banting Breast Cancer Collection (HBBCC). This breast cancer 
tissue resource located at Sunnybrook Health Sciences Centre, Toronto, has been well characterized 
for established molecular markers such as ER, PR (progesterone receptor) and HER2/Neu, along 
with  clinico-pathological  variables  and  outcomes.  By  performing  comparative  BCA2  protein 
expression analysis on tissue microarrays of the HBBCC and by using the HBBCC database, we 
obtained  clues  about  a  potential  function  of  the  E3 ligase  in  invasive  breast  cancer.  BCA2 is 
expressed  in  the  cytoplasm  and  nucleus  of  breast  cancer  tissues.  Nuclear  BCA2  expression 
however,  was the predominant  site of protein location in breast  cancer cells  (Figure 4.5). Nine 
hundred and forty-five invasive breast carcinomas of the HBBCC were evaluable for nuclear BCA2 
expression, representative tissue sections are shown in (Figure 4.5a). Four hundred and fifteen cases 
or 43.9 % of the invasive breast cancer cohort had low nuclear BCA2 levels (BCA2 intensity score 
<=1), 530 patient tissues or 56.1% of the study cohort were found to overexpress BCA2 (BCA2 
score  >1).  Some  normal  breast  tissues  also  expressed  low  amounts  of  nuclear  BCA2  protein 
(score<=1).  Sixty-seven  percent  (635)  of  the  HBBCC  breast  cancers  were  estrogen  receptor 
positive. 
Figure 4.5. (a) Comparison of BCA2 and ER expression by immunoperoxidase staining in a representative 
case of invasive breast cancer. The data reveal co-expression of ER and BCA2 in the nuclei of cells staining 
positive for the antigens (brown color: diaminobenzidine). Overall, 67% of the 945 invasive breast cancer 
cases were positive for ER and of those 74% were positive for both, ER and BCA2. (b) Colocalization of ER 
(green,  FITC-labeled  anti-mouse  antibody)  and  BCA2  (red,  TRITC-labeled  anti-rabbit  antibody)  in  the 
nuclei (merge: yellow, white arrows; nuclei were counterstained with DAPI = blue) of HEK293T cells. 
The statistical analysis of the HBBCC nuclear BCA2 protein expression study revealed that three 
variables yield significant results: first, patients with low BCA2 (57.7% of 213), were more likely 
to have lymph node metastasis at presentation than those with higher BCA2 levels (49.9% of 229, 
p=0.02). Second, women with invasive breast cancers with low BCA2 (8.6 % of 415) were more 
likely to experience regional re-occurrence than those with higher BCA2 (5.3 % of 530) (p = 0.05). 
The third significant correlation was very strong:  nuclear BCA2 expression was correlated with a 
positive estrogen receptor status (figure 4.5a).
67.1 % of all 945 invasive HBBCC cases stained positive for ER expression. 74% of breast cancers 
that were ER-positive had also nuclear BCA2>1 (p = 0.004). Because of the significant statistical 
correlation  found between invasive breast  cancers  expressing ER and BCA2,  we compared  the 
pattern of expression of these two proteins. Core by core analysis of consecutive tissue sections 
indicated that BCA2 and ER are mostly co-expressed (odds ratio = 1.5) (Figure 4.5a), cells strongly 
positive for BCA2 were positive for ER. It is important to note that high expression of BCA2 is not 
beneficial at the cellular level for inhibiting cancer progression and may be a contributing factor in 
metastasis.  However the high correlation of co-expression with ER makes  higher  expression of 
BCA2 a marker  for  good prognosis  in  breast  cancer  due to  the availability  of  highly effective 
treatment options. 12
The MDM2-p53 path and its inhibitors.
The p53 tumor  suppressor  protein  is  required  for  the  cytostatic  and  cytotoxic  effects  of  many 
anticancer agents with loss of p53 function correlating with a decrease in sensitivity to these agents. 
Adjuvant therapies that augment p53 function are predicted to sensitize cells to cancer therapies that 
rely upon p53 for their efﬁcacy. The p53 proximal regulator, MDM2, is an ubiquitin ligase that 
binds to and negatively regulates p53 stability and function. Pharmacological agents that block the 
MDM2-p53 interaction or that selectively inhibit MDM2-mediated proteolytic degradation of p53 
can  potentiate  the  anti-proliferative  properties  of  p53 in  cultured  tumor  cells  and  in  xenograft 
models, suggesting thatMDM2 antagonists may have high therapeutic  potential. 13
The first small-molecule capable to inhibits MDM2 is Nutlins (cis-imidazoline derivatives) which 
were  identified  in  a  chemical  library  screen  for  small  molecules  able  to  block  the  interaction 
between  p53  and  MDM2.  Based  on  their  structural,  biochemical  and  pharmacodynamical 
parameters, Nutlins mimic the spatial conformation of the crucial MDM2-interacting residues on 
p53 and therefore are able to occupy the p53-binding pocket and displace p53 from it. 
As expected,  Nutlins activate p53-dependent cell-cycle  arrest and apoptosis in cancer cell  lines. 
Importantly, Nutlins are effective in vivo upon oral administration: they halt the growth of nude 
mouse tumour xenografts  without noticeable  toxicity to healthy tissues.  These findings indicate 
reasonable bioavailability of these small-molecule MDM2 inhibitors.
 Another  p53-stabilizing  small  molecule  (RITA;  2,5-bis(5-hydroxymethyl-2-thienyl)furan)  was 
initially found to have anticancer activity in the National Cancer Institute Anticancer Drug Screen 
and recently  scored  as  a  hit  in  another  functional  chemical  library screen  designed to  identify 
compounds that specifically arrest growth of a p53-positive cancer cell line.
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Figure 4.6. Nutlin 3 and RITA.
 RITA is unrelated to the Nutlins both structurally and functionally. In contrast to the Nutlins, RITA 
does not seem to bind MDM2. Instead, it binds the N terminus of p53 and, although no definitive 
structural data are currently available, it seems to either prevent the recognition of p53 by MDM2, 
stabilize the N-terminal α-helix domain of p53 in the MDM2 groove, or both75. Interestingly, RITA 
seems to prevent p53 from interacting with other regulatory proteins75,  such as p53-associated 
parkin-like cytoplasmic protein (PARC, the p53 cytoplasmic anchor) and p300, which, in addition 
to  acetylating  p53  can  promote  p53  polyubiquitylation  by  MDM2 as  p53’s  ‘E4’.  The  RITA-
stabilized p53 is  transcriptionally active as it  can promote expression of endogenous p53-target 
genes.
Most excitingly,  RITA slows down the growth of mice tumour xenografts  in a dose-dependent 
manner. 2
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CHAPTER 6
                                     Inhibitors of E2, E3 enzymes
Carbamo(dithioperoxo)thioates derivatives as BCA2 inhibitors.
BCA-2 is an enzyme over-expressed in more than 57% of aggressive breast cancer carcinomas cell 
line.
Westwell et all. From the Cardiff University, have identified compounds capable to inhibit BCA2.
A precise rationale was follow for the identification of inhibitors of BCA2. 1
1. Exploring the Structural Requirements for Inhibition of the Ubiquitin E3 Ligase Breast Cancer
Associated Protein 2 (BCA2) as a Treatment for Breast Cancer
A series of molecule with a zinc- binding core capable to remove Zn2+ from the RING domain of 
BCA2 was synthesized taking as model Disulfiram (DSF), a well know compound used for fight 
alcoholism which have a zinc binding group moiety recognized in literature. 2, 3
As a matter of fact, DSF dramatically decrease the conversion of acetaldehyde to acetic acid after 
ingestion of alcohol through inhibition of human mitochondrial aldose. 
Inhibition of BCA2 by DSF is not correlated to its zinc-chelating property, but to its capacity in the 
modification of active site, as a matter, for DSF, the zinc-ejection appear to be favourite respect 
chelation mechanism.
In order to elucidate the structure-activity relationship, Brahemi et all., have synthesize disulfiram 
analogues, dithiocarbamates, benzisothiazolenes and finally carbamo(dithioperoxo)thioate (Figure 
5.1).
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Figure 5.1 Sulphur based inhibitors synthesized by Brahemi et all. as BCA2 inhibitors.1
Carbamo(dithioperoxo)thioates were synthesized refluxing the corresponding symmetrical 
Disulfiram analogue in ethanol with the appropriate thiol. 1
Scheme 5.2  Synthetic pathway for the synthesis of carbamo(dithioperoxo)thioates, product synthesized and 
inhibitory activity over cancer cell lines. 1
During the time i spent in Cardiff University under the supervision of Prof. Andrew D. Westwell, i 
synthesized novel carbamo(dithioperoxo)thioates  with various secondary amines.
Procedure used is depicted in scheme 5.3, the substituted secondary amines employed for the 
synthesis of the title compounds are report in the adjacent chart.
Tetrabromomethane was used stechiometrically in the reaction for promote the formation of 
carbamodithioperoxo bond 4. 
Hexanethiole was used as common reagent for the introduction of the alkyl chain in all the 
reactions. Almost all the reactions were carried out at room temperature using dichloromethane as 
solvent except for synthesize compound 1c, temperature was kept at 0 °C and amine was added 
very slowly because of reaction exothermicity. 
Biological evaluations are ongoing.
N
S
S
S
R
R1
NH
R
R1
SH(CH2 )5 CH3
CH2 Cl2 , N(Et)3
CBr4
1
                  
Scheme 5.3. More efficient synthetic route to carbamo(dithioperoxo)thioates.
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Triazinic derivatives as Rad6, UbcH5b.
A good amount of triazine-based scaffold BCA2 inhibitors was synthesized by previous PhD 
student Brahemi G.
He was looking for a pharmacophore capable to inhibit the binding between Ubiquitin and E2 
enzyme UbcH5b and his research culminated in the discover of a triazinic based scaffold.
  
Scheme 5.4 Pharmacophore generation and interaction with aminoacidic residues taken from Brahemi’s 
thesis.
As a matter, the library of triazines was screened in order to obtain the inhibition value on BCA2, 
an overall negative IC50 values were obtained, but two compounds shown pretty good activity 
(figure 1.5).
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Figure 5.4 Active compounds 1a and 1b.
The classical pathway started with the synthesis of biguanidine 4a and 4b from aniline or para-
toluidine and dicyanamide which were refluxed in aqueous hydrochloric acid.
The biguanidine free-base 4a, b were obtained from the corresponding hydrochloride by treatment 
with aqueous sodium hydroxide, then cyclized to triazine 5a, b with ethyl glycolate and esterified 
with 4-nitrobenzoylchloride affording 1a,b.
Actually, the cyclization step of biguandine with ethyl glycolate turned out rather ineffective , as it 
afforded the corresponding alcohol in low yields. This is why we developed another system for the 
obtainment of 1.6. 
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Scheme 5.5 Brahemi’s route to substituted triazines.
The biguanidine was cyclized with dimethyl oxalate instead of ethyl glycolate and the 
corresponding ester 7a, b was reduced with Lithium aluminium hydride in dry THF to afford with 
moderate yield the alcohol 6a, b (scheme 5.6).
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Scheme 5.6 Cyclization with dimethyloxalate and successive reduction.
But another synthetic protocol was adopt for manufacture of title compounds for further raise the 
yields. Avoiding reducing agents and dry solvents were primary objectives.
We performed a cyclization with ethyl bromoacetate and the brome derivative 8a and 8b were 
obtained in good yield. Once opportunely purified through flash chromatography, they was made 
react with 4-nitrobenzoic acid and TBAF in THF to gave the title compound in almost quantitative 
yields (scheme 5.7).
TBAF performed as a mild base which favour ester formation. 5 
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Scheme 5.7 Cyclization with ethyl bromoacetate and treatment with TBAF and 4-nitrobenzoic acid.
Title title compounds were obtained in very good yields. Washing organic phase with water and 
extracting the excess of carboxylic acid with an alkaline solution left final product almost pure.
Purification thought flash chromatography or crystallization however was necessary for high purity.
Exploiting this method, we were able to synthesize the inverse esters of title compounds depicted 
below (scheme 5.8). 
These molecules were made for a better understanding of structure - activity relationship, and for a 
better knowledge of the esteric function in the inhibition of BCA2.
Synthesis started from methyl ester 7a, b. Subsequent basic hydrolysis and acidification afforded 
the carboxylic acid 9a, b which reacted with 4-nitrobenzylbromide and TBAF in acetonitrile, 
afforded the title compound as a precipitate in the reaction environment. The powder was then 
washed with fresh acetonitrile, on Buchner funnel, and no further purification occurred.
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Biological results are expected within few months.
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CHAPTER 7
                                                 Experimental Section
General
Melting  points  were  measured  on  a  Griffin  apparatus  and  are  uncorrected.  Mass  spectra  were 
recorded on a  Bruker  MicroTOF LC instrument  or  at  the EPSRC National  Mass  Spectrometry 
Centre (Swansea, U.K.).NMRspectra were recorded on a Bruker AVANCE 500 MHz instrument; 
coupling constants (J values) are in Hz. Merck silica gel 60 (40-60 mM) was used for column 
chromatography.  All  commercially  available  starting  materials  were  used  without  further 
purification.
Scheme 5.3
General procedure for the obtainment of disulfiram analogue
(Except for N-methylpiperazine-N,N-diethyltrithioperoxocarbamate)
Carbon disulphide (6 mmol, 0.36 ml) was added to a mixture of the appropriate secondary amine 
(7.2 mmol) and thiol (7.2 mmol) in DCM (12 ml). Colour change from transparent to pale yellow.
The mixture was cooled to 0°C in an ice bath for 5 minutes, then NEt 3 (6 mmol, 0.63 ml) was 
added and the colour change from pale to bright yellow. CBr4 (6 mmol) was added and colour turn 
to brown. After two hours of stirring the reaction was partitioned between water and DCM. Water 
phase was discarded and washed with 10x3 ml of DCM. The organic phases were reunited and 
dried on MgSO4 and filtered. Solvent was removed with the aim of reduced pressure and the oily 
residue was purified through flash chromatography.1
1a. Hexyl N,N-diethyltrithioperoxocarbamate.
Flash chromatography Hexanes/AcOEt 95:5
Yield 48% as a yellow oil.
1 H  NMR (  CDCl  3)   0.90-  0.93  (3H,  t,  J =  6.50,  CH3CH2CH2),  1.10-1.35  (10H,  m,  2  x  CH3, 
CH3CH2CH2  ), 1.40 (2H, m, SCH2CH2CH2), 1.60 (2H, m, SCH2CH2), 2.80 (2H, t,  J = 6.9, SCH2), 
3.8 (2H, q, J = 6.8, NCH2), 4.0 (2H, q, J = 6.8, NCH2)
3 C NMR (CDCl  3)  11.15, 12.93, 13.80, 21.97, 27.47, 27.83, 30.82, 38.00, 46.78, 51.08, 193.96
1b. Piperidine N,N-diethyltrithioperoxocarbamate.
Flash chromatography Hexanes/AcOEt 95:5
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Yield 40% as a yellow oil.
1 H NMR (  CDCl  3)  0.90- 0.93 (3H, t, J = 6.50, CH3 (CH2) 5-),1.32 (4H, m, -(CH2)3-CH2-CH2-CH3), 
1.40 – 1.46 (2H, m, SCH2CH2CH2), 1.66 – 1.75 (8H, m,-CH2CH2CH2NCH2CH2CH2-, -SCH2CH2-), 
2.87 – 2.90 (2H, t, J = 7.7, SCH2), 4.01 (2H, s, -NCH2), 4.33 (2H, s, -NCH2). 13  C NMR (CDCl  3)  
14.01, 22.50, 24.18, 28.25, 28.55, 31.39, 38.83, 198.20. 
1c. Morpholine N,N-diethyltrithioperoxocarbamate
Flash chromatography Hexanes/AcOEt 95:5
Yield 52% as a yellow oil.
1 H NMR (  CDCl  3)  0.90- 0.93 (3H, t, J = 6.50, CH3 (CH2) 5-),1.33 
(4H, m, -(CH2)3-CH2-CH2-CH3), 1.40 – 1.46 (2H, m, SCH2CH2CH2), 1.66 – 1.72 (2H, m, ), 2.87 – 
2.90  (2H,  t,  J  =  7.7,  SCH2),  3.81  (4H,  s,  -OCH2CH2NCH2CH2-  ),  4.24  (4H,  s, 
-OCH2CH2NCH2CH2-).
13  C NMR (CDCl  3)  14.01, 22.50, 28.22, 28.59, 31.37, 38.77, 39.23, 60.30, 60.36, 198.20. 
1d. N-methylpiperazine-N,N-diethyltrithioperoxocarbamate 
Carbon disulphide (6 mmol, 0.36 ml) was added to a mixture of the 
appropriate secondary amine (7.2 mmol) and thiol (7.2 mmol) in 
DCM (12 ml).
Colour change from transparent to yellow.
The mixture was cooled to 0°C in an ice bath for 5 minutes, then NEt 3 (6 mmol, 0.63 ml) was 
added and the colour change to bright yellow. 
CBr4 must be dissolved in DCM (12 ml) and added dropwise to the reaction mixture efficiently 
cooled to 0°C. A yellow precipitate formed.
Quench the reaction with few drops of water and filter the mixture for remove the solid. The solvent 
was removed under vacuum. 
Flash chromatography AcOEt/MeOH/NEt3 95:4:1.
S
S
S
N
N
S
S
S
N
O
Yield 52% as a yellow oil.
1 H NMR (  CDCl  3) 0.90- 0.93 (3H, t,  J = 6.50, CH3  (CH2) 5-),1.33 (4H, m, -(CH2)3-CH2-CH2-
CH3), 1.40 – 1.46 (2H, m, SCH2CH2CH2), 1.66 – 1.71 (2H, m, ), 2.36 (3H, s, ), 2.53 – 2.55 (4H, t, ), 
2.87 – 2.90 (2H, t, ), 4.09 (2H, s,), 4.39 (2H, s, ). 13  C NMR (CDCl  3)  14.01, 22.50, 28.23, 28.60, 
31.37, 38.79, 45.39, 54.40, 197.67. 
1e. Pyrrolidine N,N-diethyltrithioperoxocarbamate.
Flash chromatography Hexanes/AcOEt 95:5
Yield 63 % as a yellow oil.
 1  H NMR (  CDCl  3)  0.90- 0.93 (3H, t, J = 6.50, CH3 (CH2) 5-),1.32 (4H, m, -(CH2)3-CH2-CH2-CH3), 
1.41 – 1.44 (2H, t , SCH2CH2CH2), 1.66 – 1.72 (2H, m, ), 1.99 – 2.05 (2H, t, J = ), 2.11 – 2.16 (2H, 
t), 2.87 – 2.90 (2H, t, J = 7.3 ), 3.75 – 3.78 (2H, t, J = 6.8 ), 3.98 – 4.00 (2H, t, J = 6.8 ).
13  C NMR (CDCl  3)  14.01, 22.51, 24.19, 26.30, 26.51, 28.24, 28.60, 31.39, 38.72, 50.53, 56.62, 
192.99. 
Synthesis of biguanidine.
4b. Phenylbiguanidine.
Aniline and dicyanamide were dissolved in an acidic mixture of HCl 3 N 
and refluxed for 4 hours until all the aniline reacted.
Let the reaction reach r.t. The resulting crystalline solid was collected on a Buchner funnel and 
washed with cold water.
The hydrochloride obtained was then dissolved in hot water, and NaOH 1 N was added until pH 
reach 10-11. The crystalline free base was collected again with filtration by suction and crystallized 
dissolving it in the minimum amount of hot ethyl acetate, filtered and precipitated with Hexanes.
1 HNMR (DMSO  - d  6)  7.12 (1H, t, J = 7.2, H-4), 7.21 (2H, d, J = 7.4, H-2, H-6), 7.30 (2H, t, J = 
8.6, H-3, H-5), 7.45 (5H, bs, NH2  3 x NH), 10.01 (1H, bs, NH) 13  CNMR (DMSO  - d  6)  120.41, 
120.71, 123.21, 128.33, 128.57, 138.66, 155.25, 161.15
Yield = 89%
4a. 4-methylphenylbiguanidine.
Para-toluidine hydrochloride and dicyanamide  were dissolved in water 
and refluxed for 3-4 hours. Until all the toluidine reacted.
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No Hydrochloric acid has been used.
1 HNMR (DMSO-  d  6)  2.29 (3H, s, PhCH3), 7.10 (2H, d, J = 8.4, H-2 H-6), 7.15 (1H, bs, NH), 7.25 
(2H, d,  J=8.4, H-3 H-5), 7.35 (4H, m,  NH2 NH NH), 9.8 (1H, s, NH)  13  CNMR (DMSO-  d  6)  
20.38(CH3), 121.05, 129.00, 132.41, 135.96, 155.52, 160.96.
Yield 93%.
Scheme 5.6
General method for cyclization of biguanidines.
4a or 4b (2.0 mmol) and dimethyl oxalate (118 mg, 3 eq, 6.0 mmol) was dissolved in 20 ml of dry 
methanol and stirred at r.t. under nitrogen for about 2 hours. A yellowish precipitate formed. The 
mixture was refluxed for about four hours. Purification of crude reaction product over a short pad of 
silica gel afford a crystalline product. 2
7b. methyl 4-amino-6-(phenylamino)-1,3,5-triazine-2-carboxylate.
Flash chromatography Dichloromethane/ Methanol 95:5.
Obtained 400 mg of product as white cristalline powder.
Yield 81%
1 HNMR (DMSO-  d  6)  3.78 (3H, s, COOCH3), 7.02 (1H, t, J = 7.1, H-4’), 7.05 (2H, bs, NH2), 7.32 
(2H, t, J = 7.8, H-3’, H-5’), 7.80 (2H, d, J = 7.7, H-2’,H-6’), 9.79 (1H, bs, NH). 
13CNMR (DMSO-   d 6) d 52.31, 120.09, 122.42, 128.79, 136.03, 163.78, 164.39, 165.34, 167.10.
7a. methyl 4-(p-tolylamino)-6-amino-1,3,5-triazine-2-carboxylate.
Obtained White cristalline powder.
Obtained 410 mg of product as white cristalline powder.
Yield 79%
1 HNMR (DMSO-  d  6)  2.24 (3H, s, -CH3), 3.81 (3H, s, COOCH3), 7.07-7.09 (2H, d, 2,6-H, J= 10), 
7.39 (1H,  s,  -NH2),  7.51(1H, s,  -NH2),  7.64-7.66 (2H,  d,  3,5-H),  9.86 (1H,  s,  -NH-).  13  CNMR   
(DMSO-  d  6)  20.38, 52.37, 120.16, 128.85, 131.46, 136.74, 163.93, 164.23, 165.28, 167.10.
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General method for reduction of methyl esters to alcohols
A solution of the appropriate Triazine 4a or b (1.0  mmol) in dry THF (10 ml) was added dropwise 
to a suspension of LiAlH4 (114 mg, 3 eq, 3 mmol) in 6 ml of dry THF (2ml/mmol LiAlH4).
Mixture was stirred at r.t. for about two hours, until all the starting material consumed (TLC).
Reaction was quenched with wet THF, and a 1 N solution of NaOH  was added dropwise in order to 
destroy  LiAlH4 and  dissolve  alluminates.  Mixture  was  partitioned  between  AcOEt  and  brine. 
Aqueous Layer was extracted twice with AcOEt (20 ml x 2). Organic extracts are reunited, dried 
over  MgSO4,  filtered  and solvent  was  removed  at  r.p.  The  residue  was  purified  through flash 
chromatography.
6b. (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methanol.
Flash chromatography (DCM/MeOH 9:1).
Obtained 65 mg of product (yield 39%).
HNMR (DMSO-  d  6)  4,31 (2H, J= 5,6) 4,8 (1H, t, J = 5,6 OH), 7.02 (1H 
J=7.1, H-41), 7.05 (2H, bs) 7.32 (2H, t, J = 7.8), 7.80 (2H, d, J= 7.7), 9.51 (1H, s, NH).
CNMR (DMSO-  d  6)  63.71, 119.79, 121.89, 128.32, 139.86, 164.09, 166.61, 176.90.
6a. (4-(p-tolylamino)-6-amino-1,3,5-triazin-2-yl)methanol.
Flash chromatography (DCM/MeOH 9:1) afford 65 mg of product. 
Yield 8%
Melting point: 227-228 oC
1 HNMR (  DMSO-  d  6)  2.20 (3H, s, PhCH3), 3.41 (1H, bs, OH), 4.40 (2H s, CH2OH), 5.10 (2H, s, 
NH2), 6.91 (1H, s, NH), 7.09 (2H, t, J = 8.5, H-2’ H-6’), 7.31 (2H, d, J = 8.5, H-3’ H-5’)
13  CNMR (DMSO-  d  6)  20.68, 63.79, 120.09, 122.42, 128.79, 136.03, 163.78, 164.39, 167.10.
General procedure for esterification.
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A mixture of 6a or 6b (1.0 mmol), NEt3 (1.1 eq., 1.1 mmol) and DMAP (5 mol%) was dissolved in 
dry DCM (20 ml/mmol alcool). 4-nitrobenzoyl chloride (279 mg, 1.5 eq, 1.5 mmol) in dry DCM 
(10 ml/mmol acyl chloride) was added dropwise.
The mixture was left on stirring at r.t. overnight, then brine (5 ml) was added to the reaction and the 
organic  layer  separated,  washed  with  NaHCO3 10% solution,  dried  over  MgSO4,  filtered  and 
solvent evaporated in vacuo.
1b. (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-
nitrobenzoate.
Flash  chromatography  (AcOEt/Hexane  5:5  )  afforded  title 
c ompound
Yield 50%.
Melting point: 168-169 oC
1 HNMR (DMSO  - d  6)  5.18 (2H, s, CH2O), 6.80 (1H, m, H-4’), 7.15 (4H, m, NH2 H-2’ H-6’), 7.62 
(2H, m, H-3’ H-5’), 8.25 (2H d, J = 8.9, H-2” H-6”), 8.40 (2H, d, J = 8.8, H-3” H-5”), 9.48 (1H, s, 
NH)  13  CNMR  (DMSO-  d  6)   65.48,  119.89,  122.05,  123.67,  128.16,  130.65,  134.90,  139.53, 
150.38, 159.00, 164.05, 166.51, 172.11
 1a. (4-(p-tolylamino)-6-amino-1,3,5-triazin-2-yl)methyl  4-
nitrobenzoate.
Flash  chromatography  (AcOEt/Hexane  5:5  )  afforded  title 
compound.
Yield 70%.
1 HNMR (DMSO  -d  6)  2.18 (3H, s, PhCH3), 5.17 (2H, s, CH2O), 6.96 (2H, bs, NH2), 7.01 (2H, m, 
H-2’ H-6’), 7.50 (2H, m, H-3’ H-5’), 8.21 (2H, d, J = 8.7, H-2” H-6”), 8.2 (2H, d, J = 8.7, H-3” H-
5”)  13  CNMR (  DMSO  -d  6)  20.26, 59.71, 120.13, 123.89, 128.54, 130.93, 134.94, 136.87, 138.00 
150.36, 163.94, 164.05, 166.50, 171.98 
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Scheme 5.7
General procedure for the obtainment of 8a 8b.
4a  or  4b  (5.21  mmol)  was  dissolved  in  methanol  (1ml/mmol)  then,  under  stirring,  ethyl 
bromoacetate (865 mg, 5.21 mmol) was added dropwise. The reaction mixture was allowed to stir at 
room temperature overnight. The solvent was then removed with the aim of reduced pressure. The 
brownish residue was purified through flash chromatography affording the product. 
8b. 6-(bromomethyl)-N2-phenyl-1,3,5-triazine-2,4-diamine.
Flash chromatography (Hex/ AcOEt 6:4)
Yield 43%
1 HNMR (DMSO-  d  6)   4.18 (2H, s, BrCH2-),  7.02 (1H, t,  J = 7.1, H-4’), 
7.05 (2H, s, NH2), 7.32 (2H, t,  J = 7.8, H-3’, H-5’), 7.80 (2H, d,  J = 7.7, H-2’,H-6’), 9.51(1H, s, 
NH). 13CNMR (DMSO-   d 6)  33.89, 119.89, 121.92, 128.32, 137.06, 164.09, 164.61, 172.90
8a. 6-(bromomethyl)-N2-p-tolyl-1,3,5-triazine-2,4-diamine
Flash chromatography (Hex/ AcOEt 6:4)
Yield 39%
Melting Point 170°C (Dec.)
1 HNMR (DMSO-  d  6)  2.24 (3H, s, PhCH3), 4.18 (2H, s, BrCH2-), 7.07-7.10 (2H, d, 2,6-H), 7.19 
(2H,s, -NH2), 7.62-7.65 (2H, d, 3,5-H), 9.52 (1H, s, NH). 13  CNMR (DMSO-  d  6)  20.36, 33.91, 
120.08, 128.85, 131.19, 136.92, 164.37, 167.05, 172.95.
Scheme 5.6, 5.7.
General method for the synthesis of title compounds 1a, 1b.
In a round bottomed flask 8a or 8b (0.34 mmol) and 4-nitrobenzoic acid ( 120 mg, 0.68 mmol, 2eq) 
was dissolved in THF (12 ml). TBAF (1.4 ml, 2 eq, 1.4 mmol, 1M sol in THF) was added dropwise. 
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Reaction mixture was heated to reflux untill completion (2 hours). THF was then removed in vacuo, 
and the highly viscous residue was partitioned between AcOEt (50 ml) and water (10 ml x 2), then 
with a saturated solution of NaHCO3 (10 x 3) until neutral to litmus paper. The organic phase was 
dried over MgSO4 and filtered. AcOEt was removed in vacuo. The yellowish residue was purified 
through flash chromathograpy (CH2Cl2/ MeOH 98:2). An analitycal sample can be obtained through 
cristallization from acetonitrile affording very small yellow crystals. 3
1b. (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-
nitrobenzoate.
Yield 86%
Melting Point 148-150 oC                        
1 HNMR (DMSO-  d  6)  5.22 (2H, s, CH2O), 6.90 (1H, s, NH), 
7.09 (3H, m, H-2’,H-4’,H-6’), 7.61 (2H, t, J = 7.9, H-3’, H-5’), 7.72 (3H, m, H-3”,H-4”,H-5”), 8.13 
(2H, d, J = 7.2, H-2”, H-6”), 9.01 (1H, bs, NH)
13  CNMR (CDCl  3)  64.89, 119.80, 121.91, 128.13, 128.77, 129.31, 129.54, 133.45, 139.61, 164.02, 
165.45, 166.51, 172.56.
1a. (4-(p-tolylamino)-6-amino-1,3,5-triazin-2-yl)methyl 4-
nitrobenzoate.
Yield 79%
Melting Point 172-173 oC
1 HNMR (DMSO-  d  6)  2.18 (3H, s, -CH3), 5.15 (2H, s, 
-CH2Br), 7.04 (4H, s -NH2, 2,6-H), 7.52 (2H, s, 3,5-H), 8.27-8.29 (2H, 2,6-H), 8.39-8.41 (2H, 3,5-
H), 9.38 (1H, -NH-). 13  CNMR (CDCl  3)  19.81, 65.36, 120.04, 120.14, 123.29, 128.48, 130.83, 
131.31, 135.75, 137.22, 150.78, 163.77, 164.68, 167.47.
Scheme 5.8
General procedure for the obtainment of carboxylic acid 9a, 9b.
9a or 9b (1.00 mmol) was dissolved in 50 ml of ethanol, 10 ml of 1 N solution of NaOH was added. 
The mixture was refluxed for three hours untill consumption of starting material.
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The reaction was left cool to r.t. and the solvents removed in vacuo.
The residue was acidified with HCl 1 N (about 10 ml) untill the solution reach a strong acidic pH 
(1-2). Filter the precipitate on a buchner funnel, wash it with plenty of water and 10 ml x 2 AcOEt. 
Then let it air dry.
9b. 4-amino-6-(phenylamino)-1,3,5-triazine-2-carboxylic acid.
Melting Point > 250°C
Yield 94 % as a white to yellowish solid.
1HNMR  (DMSO-d6) 9.85 (s, 1H), 7.65- 7.63 (d, 2H, J= 10 Hz), 7.41 (s, 
2H), 7.10 – 7.08 (d, 2H, J= 10 Hz). 13CNMR (DMSO-  d  6) 166.81, 165.25, 164.97, 164.15, 136.72, 
131.45, 128.88, 120.15.
9a. 4-(p-tolylamino)-6-amino-1,3,5-triazine-2-carboxylic acid.
Melting Point > 250°C
Yield 91 % as a white to yellowish solid.
1HNMR (DMSO-d6) 9.80 (s, 1H), 7.66- 7.64 (d, 2H, J= 10 Hz), 7.40 (s, 2H), 7.10 – 7.08 (d, 2H, J= 
10 Hz), 2.26 (s, 3H). 13CNMR (DMSO-  d  6) 166.78, 165.28, 164.97,164.18, 136.74, 131.46, 128.85, 
120.16, 20.37.
Scheme 5.8.
General method for the synthesis of title compounds 10a-10f.
In a round bottomed flask 9a or 9b (1.00 mmol) and the appropriated mono nitrobenzoyl chloride 
( 237 mg 1.1 mmol, 1.1 eq)  was dissolved in acetonitrile (14 ml). TBAF (1.4 ml, 2 eq, 1.4 mmol, 
1M sol in THF) was added dropwise. Reaction mixture was stirred overnight.  
A yellowish precipitate formed. Collect the stuff on a buchner funnel and triturated the compound 
with  fresh  acetonitrile.  An  analitycal  sample  can  be  obtained  through  cristallization  from 
acetonitrile affording very small crystals. 3
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10a. 2-nitrobenzyl 4-amino-6-(phenylamino)-1,3,5-triazine-2-
carboxylate.
Yield = 93%
1HNMR (DMSO-  d  6) 9.94 (s, 1H), 8.20 – 8.18, 7.84 – 7.79 (m, 4H), 
7.69 – 7.66 (t) 7.61 (s, 1H) 7.46 (s, 1H), 7.31- 7.28 (t), 7.04 – 7.01 (t), 5.69 (s, 2H). 13CNMR 
(DMSO-d6) 166.01, 163.21, 162.59, 161.78, 146.23, 138.17, 133.16, 129.83, 128.45, 127.30, 
123.90, 121.44, 119.01, 62.45.
10b.  2-nitrobenzyl  4-(p-tolylamino)-6-amino-1,3,5-triazine-2-
carboxylate.
Yield = 82%
Melting Point 203 – 204°C
1HNMR  (DMSO-  d  6) 9.86 (s, 1H) 8.20 – 8.18 (d, 1H, J= 10 Hz), 
8.18 – 7.79 (t, 2H), 7.69 – 7.65 (m, 3H), 7.56 (s, 1H, NH), 7.43 (s, 1H, NH), 7.10 – 7.09 (d, 2H, J= 
5  Hz),  5.69  (s,  2H),  2.26  (s,  3H). 13CNMR  (DMSO-d6)  167.11,163.67,162.94,136.69,  134.28, 
131.53,130.97, 129.57, 128.84,125.01, 120.22, 63.53, 20.39.
10c.  3-nitrobenzyl  4-amino-6-(phenylamino)-1,3,5-triazine-
2-carboxylate.
Yield = 62.4 %
Melting Point 189°C
1HNMR (DMSO-  d  6) 9.92 (s, 1H, NH), 8.35 (s, 1H,) 8.25- 8.23 
(d, 1H, J = 10 Hz) 7.94- 7.93 (d, 1H, J=5), 7.80-   7.80- 7.78 (d, 1H) 7.75- 7.72 (t, 1H, Jmin = 10, 
Jmax = 15)  7.59 (s, 1H, -NH2),  7.44(s, 1H, -NH2)  7.30- 7.26 (t, 2H, Jmin= 10 Jmax = 20 Hz) 
7.03- 7.00 (t, 1H, Jmin = 10, Jmax = 15 Hz) 5.48 (s, 2H). 13CNMR (DMSO-  d  6) 167.09 164.28 
163.86 163.13 147.81 139.29 137.73 134.94 130.16 128.41 123.23 123.01 122.53 120.07 65.65.
10d. 3-nitrobenzyl 4-(p-tolylamino)-6-amino-1,3,5-triazine-
2-carboxylate.
Yield = 72%
Melting Point 207-209°C
1HNMR  (DMSO-  d  6)  9.84 (s, 1H, NH), 8.34 (s, 1H,) 8.25 (s, 
1H) 7.94- 7.92 (d, 1H, J=10), 7.80- 7.78 (d, 1H) 7.75- 7.72 (t, 1H, Jmin = 10, Jmax = 15)  7.66 (d, 
2H, -NH2), 7.54 (s, 1H, -NH2) 7.42 (s, 1H, -NH2)  7.10 (s, 2H, Jmin= 10 Jmax = 20 Hz) 5.48 (s, 
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2H), 2.25 (s, 3H).  13CNMR  (DMSO-d6)167.08, 164.19, 163.81, 163.17, 147.80 ,137.75, 136.70, 
134.94, 131.50, 130.16, 128.82, 123.23, 123.01, 120.19, 65.61, 20.38.
10e.  4-nitrobenzyl  4-amino-6-(phenylamino)-1,3,5-triazine-2-
carboxylate.
Yield = 67%
Melting Point 218°C
1HNMR (DMSO-  d  6) 9.93 (s, 1H, NH) 8.28- 8.27 (d, 2H, ArH, J= 
8.75 Hz) 7.80- 7.79 (d, 2H, ArH, J= 10) 7.74- 7.72 (d, 2H, ArH, J= 10) 7.60 (s, 1H, -NH2) 7.45 (s, 
1H, -NH2) 7.30 - 7.27 (t, 2H, J min = 10, Jmax = 16 Hz) 7.03- 7.00 (t, 1H,)  5.50 (s, 2H, ArCH2-). 
13CNMR  (DMSO-  d  6) 167.10 164.29 163.83 163.08 147.29 143.17 139.29 128.96 128.41 123.62 
122.55 120.10 65.54.
10f. 4-nitrobenzyl 4-(p-tolylamino)-6-amino-1,3,5-triazine-
2-carboxylate.
Yield = 55 %
Melting Point 246-248°C
1HNMR (DMSO-  d  6) 9.85 (s, 1H, NH), 8.28 – 8.27 (d, 2H, J= 5 
Hz), 7.73 – 7.71 (d, 2H, J= 10 Hz), 7.66 – 7.65 (d, 2H, J= 5 Hz), 7.55 (s, 1H, NH) 7.42 (s, 1H, NH), 
7.10 – 7.08 (d, 2H, J= 10 Hz), 5.49 (s, 2H), 2.26 (s, 3H). 13CNMR (DMSO-  d  6)  167.10, 164.22, 
163.79,163.12,147.28,143.18, 136.69, 131.53, 128.94, 128.83, 123.61,120.22, 65.499, 20.37.
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